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ABSTRACT 
 
Abigail Norris Turner 
HIV and STI among women in Uganda, Zimbabwe and Thailand: 
Associations with male circumcision and changes in condom use 
(Under the direction of William C. Miller) 
 
 
The results of most HIV-prevention programs over the 25-year history of the AIDS 
epidemic have been disappointing. Two interventions have been notable exceptions 
in the string of prevention failures: in 1983, researchers reported that consistent use 
of male condoms reduced risk of HIV transmission, and much more recently, in 
February 2007, large-scale randomized trials determined that circumcision reduced 
men’s risk of HIV acquisition by 40-65%. These separate interventions - male 
circumcision and condom use - are the focus of these dissertation analyses.  
 
We examined whether the circumcision status of women’s primary sexual partner 
was associated with her risk of HIV and three sexually transmitted infections (STIs): 
Chlamydia trachomatis (Ct), Neisseria gonorrhoeae (GC), and Trichomonas 
vaginalis (Tv). We used data from a prospective cohort study on hormonal 
contraception and incident HIV and STI (HC-HIV study) among women from 
Uganda, Zimbabwe and Thailand (HIV analyses included 4,417 Ugandan and 
Zimbabwean women; STI analyses included 5,925 women from Uganda, Zimbabwe 
and Thailand). After adjustment, women with circumcised partners had similar risk to 
iv 
women with uncircumcised partners for HIV (hazard ratio (HR): 1.03, 95% 
confidence interval (CI): 0.69-1.53), Ct (HR: 1.22, 95% CI: 0.94-1.59), GC (HR: 0.93, 
95% CI: 0.70-1.24), and Tv (HR: 1.05, 95% CI: 0.81-1.37). 
 
Among women who became HIV-infected during HC-HIV, we also examined 
whether HIV diagnosis, together with counseling and free condoms, was sufficient to 
induce changes in women’s condom use over both short (2-6 months) and longer 
time periods (12-16 months). After diagnosis, the number of HIV-infected women 
reporting any unprotected acts in a typical month declined significantly (short-term: 
from 72% to 56%; long-term: from 74% to 56%). After adjustment, among women 
reporting any unprotected acts, HIV-infected women also reduced the number of 
unprotected acts by 29% (short term) and 38% (long term). When assessing the 
proportion of acts where male condoms were used, however, women had no 
reduction over time.  
 
Circumcision was not associated with women’s risk of HIV, Ct, Tv or GC among 
most participants. HIV-infected women reduced their overall number of unprotected 
sex acts, but the proportion of unprotected acts was unchanged from pre-infection 
behavior.
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CHAPTER 1:  SPECIFIC AIMS 
 
Overview 
The World Health Organization (WHO) estimates that over 340 million new cases of 
curable sexually transmitted infections (STIs) occur among adults worldwide each 
year. In addition, as of December 2006, nearly 40 million people were living with 
human immunodeficiency virus (HIV). The vast majority of both STI and HIV 
infections occur in developing countries, and within these resource-poor settings, 
women suffer a disproportionate disease burden. Prevention strategies that may 
lower women’s risk of acquiring HIV/STI are therefore an important research priority 
worldwide. We explored two research areas that may ultimately lead to interventions 
to reduce women’s risk of STI and HIV, thereby reducing the serious morbidities 
(and in the case of HIV, mortality) associated with these infections.  
 
In a prospective cohort of 6,109 Ugandan, Zimbabwean and Thai women, we 
examined the role of male circumcision (MC) on women’s risk of acquiring HIV/STI. 
In a subgroup of Ugandan and Zimbabwean women, we compared women’s 
condom use from the period several months prior to HIV diagnosis with that reported 
in the months and year following notification of HIV-positive status. 
 
 
2 
MC and female partners’ risk of acquisition of HIV/STI 
Associations between MC and men’s risk of HIV/STI have been well studied; 
circumcised men appear to have significantly lower risk of HIV acquisition compared 
to uncircumcised men. The subsequent risk to men’s female sex partners, however, 
is not known. The inner layer of the foreskin is a repository for shed cells and a 
hospitable environment for growth of bacteria and other microorganisms, possibly 
resulting in a higher burden of infectious organisms in uncircumcised men and 
therefore a greater risk of transmission to women. In addition, when the inner layer 
of the foreskin becomes exteriorized during intercourse, uncircumcised men may 
expose a greater infectious “surface area” to their partners, increasing the likelihood 
that women will be exposed to sexually-transmitted pathogens. Finally, MC may 
have no direct effect on the transmissibility of HIV or STIs from infected men to 
susceptible women, but if circumcision reduces men’s disease risk, women 
partnered with circumcised men may be less likely to be exposed to sexually 
transmitted pathogens. 
 
Changes in self-reported condom use following notification of HIV-positive status  
Although male condoms are the most effective method currently available to prevent 
HIV transmission, condom use remains low in many populations. Much of the 
counseling delivered through HIV prevention programs encourages individuals to 
increase their use of male condoms. Few studies, however, actually measure 
behaviors before and after infection; they assume instead that pre-counseling 
behavior was sufficiently risky to lead to infection, and that self-reported increases in 
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condom use, or lower rates of subsequent STI or pregnancy, are evidence of a 
successful counseling intervention. When the behavior of recently HIV-infected 
individuals has been examined, the results are mixed: some individuals continue to 
engage in risky sexual behavior, while others report a period of sexual abstinence 
following infection. Our analysis compares reported condom use in the period prior 
to infection with condom use several months and one year after notification of HIV-
positive status. 
 
Specific Aim 1 
To examine primary partner’s circumcision status, as reported by their female sex 
partners, as a risk factor for women’s acquisition of HIV and three treatable STIs: 
Chlamydia trachomatis (Ct), Neisseria gonorrhoeae (GC), and Trichomonas 
vaginalis (Tv) (each outcome modeled separately).  
 
Aim 1 hypotheses: 
We hypothesized that time to HIV infection, and time to first infection with Ct, GC, or 
Tv, would be shorter for women whose primary partners were uncircumcised than 
for women whose primary partners were circumcised. 
 
(Analyses addressing Specific Aim 1 are presented in two chapters. Chapter 4 
examines the effect of MC on women’s risk of HIV acquisition, and Chapter 5 
examines the effect of MC on women’s risk of chlamydial, gonococcal and 
trichomonal infection.)  
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Specific Aim 2 
To examine the association between notification of HIV-positive status and changes 
in women’s self-reported use of male condoms.  
 
Aim 2 hypotheses:  
1. We hypothesized that women who were notified of HIV-positive status two to 
six months previously would report higher condom use than they had in the 
pre-diagnosis period, and that HIV-negative participants’ condom use over 
the same period would be unchanged.  
2. We hypothesized that women who were notified of HIV-positive status twelve 
to sixteen months previously would report similar condom use as they had 
reported in the pre-diagnosis period, and that HIV-negative participants’ 
condom use over the same period would also be unchanged.
  
 
 
 
 
 
 
 
CHAPTER 2: INTRODUCTION 
 
HIV/STI in women  
Women face disproportionately high HIV/STI prevalence. WHO estimates that over 
340 million new cases of curable STIs occur among adults worldwide each year.
1
 In 
addition, as of December 2006, nearly 40 million people were living with HIV.
2
 The 
vast majority of both STI and HIV infections occur in developing countries, and 
within these resource-poor settings, women suffer a disproportionate disease 
burden. For example, 57% of HIV infections in sub-Saharan Africa, the region 
experiencing the most severe HIV epidemic, occur in women and girls.
2
 Cultural, 
socioeconomic and biologic factors all contribute to women’s greater STI 
vulnerability. Poor health infrastructure, limited economic resources and cultural 
stigma may restrict women’s access to treatment, and some women may also fail to 
seek out timely medical care because their infections are asymptomatic. When they 
are treated, security and cultural considerations may make women unable or 
unwilling to deliver partner treatment, consequently leaving them vulnerable to re-
exposure and re-infection.
3-5
 In addition, because of a number of physiological 
factors, women are biologically at higher risk than men when exposed to STI and 
HIV.
6
 Development of prevention strategies that may lower women’s risk of 
acquiring HIV/STI is an important research priority worldwide. 
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Male circumcision and women’s risk of HIV/STI acquisition (Aim 1) 
 
Male circumcision: history and prevalence 
MC is a simple surgery in which the foreskin (prepuce) is removed. The prepuce is 
the fold of skin over the glans of the penis, composed of an outer keratinized layer 
and an inner mucosal layer; this inner layer lines a preputial sac. The prepuce is 
thought to protect the glans from drying out and keratinizing.  
 
MC took place throughout the ancient world. Historians hypothesize that 
circumcision was performed for a variety of reasons, including hygiene, for infection 
prevention, in ceremonial sacrifice, to emasculate enemies after battle defeat, as 
cultural identity (similar to a tattoo), and to cure countless medical and social 
problems, including epilepsy, headache, rectal prolapse, asthma, gout, clubfoot and 
alcoholism.
7,8
  
 
Approximately 25% of the male population worldwide is circumcised,
9
 although MC 
is substantially more common in the US (in 1999, 1.2 million infant boys in the US 
(65% of newborn males) were circumcised).
7
 In many parts of the world, only 
particular religions (including Islam and Judaism) prescribe the surgery. In Europe 
circumcision is fairly rare outside these religious groups,
10
 whereas in the United 
States, circumcision is often performed at birth regardless of religious affiliation. In 
1999 the American Academy of Pediatrics (AAP) revised their policy on 
circumcision: “Scientific studies show some medical benefits of circumcision. 
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However, these benefits are not sufficient for the AAP to recommend that all infant 
boys be circumcised.”
11
 In some regions (including sub-Saharan Africa), 
circumcision may be performed in infancy or at puberty as a rite of passage into 
manhood.
12
  
 
Because of intense media attention given to the results of recent randomized trials 
documenting MC’s protective effect against HIV acquisition by men (see below), 
uncircumcised adult men in parts of Africa are reportedly now requesting 
circumcision from providers.
13,14
  The recent swell in requests for circumcision 
surgeries may alter typical circumcision practices across the African continent; until 
now, prevalence of male circumcision has varied by region from close to 0% to close 
to 100%.
15
 Generally, countries in West and Central Africa have higher circumcision 
prevalence (more than 60% of men circumcised), whereas those in Southern Africa 
have lower circumcision prevalence (fewer than 40% circumcised), although 
exceptions exist (Figure 2.1, published in reference 15, data from references 16 and 
17). Circumcision correlates in part with the presence of Islam: men in largely 
Muslim countries are typically circumcised.
18
 In other regions, however, cultural and 
traditional practices prescribe circumcision regardless of religious creed.
18
 An 
inverse, ecologic relationship between circumcision prevalence and HIV prevalence 
has been noted (Figure 2.1).
15,18
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MC and men’s risk of HIV acquisition 
Male circumcision appears protective against HIV acquisition. Three randomized 
clinical trials (RCTs) evaluating the association between MC and men’s HIV risk, 
conducted in South Africa,
19
 Uganda
20
 and Kenya,
21
 were independently stopped 
early by their respective data safety monitoring boards when interim analyses 
showed that circumcised men had 40-65% reduced risk of incident HIV infection 
compared to uncircumcised men. 
 
Prior to the recent RCTs, more than 50 studies of various designs, including several 
meta-analyses and systematic reviews,
22-26
 had evaluated the MC-HIV association 
in men. The large majority suggested that circumcised men have lower HIV risk than 
their uncircumcised peers. One 2005 modeling analysis concluded that the per-act 
risk of transmission from an HIV-infected woman to an uninfected, uncircumcised 
man is more than twice that for a circumcised man.
27
  
 
MC and men’s risk of STI acquisition 
Lack of MC is also a hypothesized risk factor for acquisition of various STIs, 
including possible links with herpes simplex virus (HSV), gonorrhea, syphilis, 
chancroid, chlamydia and genital warts.
28,29
 Evidence of the influence of MC on 
men’s risk of gonococcal, chlamydial and trichomonal infection is inconclusive. 
Uncircumcised men had higher risk of gonorrhea in several studies,
30-35
 but other 
analyses report no substantial association between circumcision status and 
GC.
18,32,36-40
 A preponderance of evidence suggests that circumcision status does 
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not affect men’s risk of chlamydial infection. Although three studies found increased 
risk of Ct infection among uncircumcised men,
34,41,42
 many others
18,30-32,38-40,43-47
 
found no association. Many of these analyses were conducted on very small sample 
sizes or included small numbers of Ct cases. Insufficient data exist to examine the 
association between male circumcision and trichomoniasis. Two studies (cross-
sectional
39
 and ecologic
48
) both noted no association, but additional research is 
needed to evaluate any causal link.  
 
Several biologic mechanisms may explain uncircumcised men’s increased HIV/STI 
risk:
49-51
 1) the nonkeratinized, inner layer of the prepuce may be more susceptible 
to traumatic epithelial disruptions during intercourse, permitting STI pathogens to 
move through microscopic abrasions;
7,52,53
 2) the preputial sac may act as an 
incubating microclimate, promoting survival of STI microorganisms; 3) the presence 
of the foreskin may decrease STI detection, thereby increasing the likelihood both of 
complications and further transmission;
6
 4) (for HIV acquisition) the highly 
vascularised prepuce contains high densities of HIV target cells (CD4 T cells, 
Langerhans cells, and macrophages), which bear the CCR5 and CXCR5 chemokine 
receptors involved in HIV acquisition. The concentration of these cells in the 
prepuce is higher than in cervical, vaginal or rectal mucosa;
43,54
 and 5) (for HIV 
acquisition) uncircumcised men appear to be at higher risk of genital ulceration and 
balanitis, which facilitates HIV acquisition.
54,55 
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The foreskin also has several protective functions, complicating disease prevention 
efforts related to MC. Some researchers postulate that the foreskin has numerous 
immunological functions that confer protection against HIV/STI. The prepuce 
contains apocrine glands, which secrete cathepsin B, lysozyme, chymotrypsin, 
neotrophil elastase, cytokine, and pheromones such as androsterone.
56-59
 Lysozyme 
destroys bacterial cell walls and attacks HIV.
56,60,61
 Animal studies also suggest that 
hydrogen peroxide and halide or pseudohalides are present in the prepuce,
56,62
 and 
this combination forms a powerful antimicrobial system that is effective against a 
variety of microorganisms.
63
 Additionally, circumcision opponents argue that there 
may be no meaningful difference in the keratin layer covering the glans of the penis 
between circumcised and uncircumcised men (thereby refuting the argument that 
circumcision is protective because of this keratonization). They cite a study of 13 
cadavers in which no substantial difference in keratonization was seen between 
circumcised and uncircumcised men.
51
  
 
Men’s circumcision status and women’s HIV/STI risk 
Almost all existing literature assesses the change in disease risk for men due to MC, 
without further evaluating how such changes may affect the risk of HIV/STIs to their 
female sex partners. It is this effect, men’s circumcision status on women’s risk of 
acquiring HIV and other STIs, which we address.  
 
Circumcision may have a protective effect on women’s HIV risk. Although only a 
handful of studies have been published, available evidence suggests that women 
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partnered with uncircumcised men are at higher risk of HIV acquisition than women 
partnered with circumcised men (Table 2.1).  
 
Prospective studies from two groups suggest that women with uncircumcised 
partners have higher HIV risk than women partnered with circumcised men. In 1998, 
urban Tanzanian women with uncircumcised husbands had significantly increased 
HIV risk compared to women with circumcised husbands (adjusted RR=3.4).
64
 A 
couples study in rural Uganda (the Rakai Project) published in 2000 among HIV-
positive men and HIV-negative women found that the women who were partnered 
with uncircumcised men had significantly higher HIV risk compared to those 
partnered with circumcised men (adjusted RR=2.4; authors report inverse 
RR=0.4).
65,66 
A third report in 2006, also from the discordant couples in the Rakai 
Project in Uganda, reported that women with uncircumcised partners had an 
elevated, though non-significant, rate of HIV acquisition compared to women whose 
partners were circumcised (unadjusted incidence rate ratio=1.6, authors report 
inverse IRR=0.64).
67
 
 
Cross-sectional studies generated some mixed results, but the bulk of the evidence 
again suggests that male circumcision is protective against HIV acquisition by 
female partners. Women in Kenya partnered with uncircumcised men were 
significantly more likely to be HIV-infected than women whose partners were 
circumcised (adjusted OR=2.9).
68
 A couples study in Uganda reported that women 
in HIV-concordant couples were more likely to have an uncircumcised partner than 
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women in HIV-discordant couples (adjusted OR=6.5).
69
 Women in Brazil who were 
partnered with uncircumcised HIV-infected men had a higher prevalence of HIV than 
women whose partners were circumcised (unadjusted OR=2.5; authors report 
inverse OR=0.4).
70
 Contrary to the other literature, a study of Rwandan women 
found that having an uncircumcised partner was not significantly associated with 
HIV prevalence (HIV prevalence=29% in women with circumcised husbands and 
31% in women with uncircumcised husbands),
71
 and a separate study of pregnant 
Rwandan women found that those with uncircumcised partners had a decreased 
prevalence of HIV compared to women with circumcised partners (unadjusted POR= 
0.3, authors report inverse POR=3.5).
72
 
 
Circumcision has an unknown effect on women’s risk of STIs (Table 2.1). Two 
studies have explored circumcision as a risk factor for women’s Ct acquisition.
67,73
 
The first, a case-control study of 305 couples, found that lack of MC was strongly 
associated with increased odds of Ct seropositivity in female partners (OR of 5.56; 
authors report inverse OR of 0.18).
73
 The second, described above,
67
 was designed 
to explore the association between MC and women’s risk of incident HIV, but the 
investigators also examined prevalent Ct, GC and Tv infections in women:
67
  
comparing women with uncircumcised partners to those with circumcised partners, 
for Ct, the PRR was 0.94 (authors report inverse PRR=1.06); for GC, PRR=0.84 
(authors report inverse PRR=1.19); and for Tv, PRR=1.54 (authors report inverse 
PRR=0.65).
67
 Only the association with Tv was significant (MC was protective).  
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Proposed biologic mechanisms linking MC with women’s HIV/STI risk  
If uncircumcised men have a higher efficiency of transmitting STI pathogens, 
including HIV, their partners may have increased risk of acquisition of these 
infections. When the inner layer of the foreskin becomes exteriorized during 
intercourse, uncircumcised men may expose a greater infectious “surface area” to 
their partners, increasing the likelihood that women will come into contact with 
HIV/STI organisms. In addition, the inner layer of the foreskin is a repository for 
shed cells and a hospitable environment for the growth of microorganisms, possibly 
leading to a higher burden of infectious organisms in uncircumcised men and 
therefore a greater risk of passage of these pathogens to women. HIV/STI-infected 
uncircumcised men may be more infectious than HIV/STI-infected circumcised men. 
When male foreskins and female ectocervices from HIV-positive individuals were 
cultured, foreskins contained nine times the amount of HIV DNA than that found in 
cervical tissue. In contrast, HIV DNA from the outer surface of the foreskin, which is 
keratonized like that of a circumcised penis, was below the limits of detection.
7,74
 A 
study of tissue samples from macaques with simian immunodeficiency virus (SIV) 
reported SIV-infected cells in the dermis, epidermis, and mucosal epithelium of the 
penile foreskin.
75,76
 Lastly, uncircumcised men who are coinfected with ulcerative 
STIs may shed HIV and other bacterial STIs more prolifically than circumcised men. 
 
Misclassification of MC 
Because MC in our analyses was self-reported by female partners, we also explored 
the role of misclassification of men’s circumcision status. In the 1950s, a large US 
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study reported extremely low sensitivity (44%) and less-than-stellar specificity (83%) 
for men’s reporting of their own circumcision status.
77
 If such misclassification exists 
but goes undetected, and the misclassification is nondifferential with respect to 
disease status, the true effect of MC would be more extreme than what is reported 
in many studies.
43,78 
 
In response to threats to validity from misclassification of circumcision status, 
several studies have quantified the accuracy of circumcision measures by 
comparing to the “gold standard” of clinician verification (Table 2.2). Of particular 
relevance, four studies examined the accuracy of women’s classification of their 
partner’s circumcision status.
79-81 (and R. Gray, unpublished)
 Compared to clinician-recorded 
circumcision, Rwandan women’s reports in one study were 94% sensitive and 89% 
specific.
79
 A decades-old US study of cervical cancer reported that women assessed 
their husband’s circumcision status with 70% sensitivity and 79% specificity 
compared to clinician examination.
81 
Of note, 19-27% did not know whether their 
husbands were circumcised.
81
 A third study, also conducted in the US, queried men 
and women separately about the circumcision status of the male partner. The 
authors reported that both partners had fairly high sensitivity (92%) and specificity 
(94%) in identifying the male’s circumcision status.
80
 The fourth report, unpublished, 
is from a couples study in Rakai, Uganda, compared women’s reports about their 
partners to the men’s reports and found that women classified MC with 92% 
sensitivity and 97% specificity (Ron Gray, unpublished data). 
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Notification of HIV status and condom use among women (Aim 2) 
 
Women in resource-poor regions have higher HIV/STI rates and face greater 
morbidities as a result of HIV/STI infection than their male counterparts. This 
disparity has many causes, and solutions involve both individual behavioral 
modification and societal changes to traditional sexual norms. Our analysis 
examined one behavioral change – increased male condom use – and the role that 
HIV diagnosis plays in inducing and sustaining this change.  
 
Public health interventions are often targeted to reach individuals at the moment of 
disease diagnosis, since those affected may initially have increased motivation to 
respond to the intervention. In the case of HIV diagnosis, since results are usually 
given in clinical settings, the availability of immediate counseling may make women 
more open to the training and tools (e.g. condoms) provided to facilitate change. 
 
Nevertheless, a positive HIV diagnosis may lead to at least three disparate 
outcomes: it may be an incentive for behavior change to avoid future transmission, 
and therefore risk-taking may decrease; it may lead to no change in risky behaviors, 
if the infection is not associated with sufficient worry to the individual or she lacks 
skills to avoid future transmission; or it may lead to increased risky behavior, since 
“the worst” has now happened and the individual has no incentive to limit risk-
taking.
82
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Changes in many types of behavior are possible following HIV diagnosis, such as 
reducing the number of new and existing sexual partners, or eliminating concurrent 
partnerships. Because our cohort enrolled largely married, monogamous women – 
most of whom already avoided these risky behaviors – we focused instead on 
changes in use of male condoms.  
 
Male condoms and HIV/STI prevention 
Although the subject of some political debate in recent years,
83,84
 latex male 
condoms, when used consistently and correctly, are effective against sexual 
transmission of HIV and most STIs.
85-88
 Analyses considering manufacturer failure 
rates, user failure rates, pathogen characteristics and other factors found 
effectiveness statistics ranging from 69%-95% against HIV.
89,90
 It is generally 
accepted that intact latex condoms provide an effective barrier to HIV-sized 
particles, though transmission is possible when condoms break or slip.
91
 
 
Condoms are also important for population-level control of STIs, including HIV. 
Simulation models suggest that condom use can significantly alter population 
disease prevalence. For STIs with high transmission rates (e.g., gonorrhea), 
consistent condom use can adequately control disease spread.
92
 For low-
transmission STIs (e.g. HIV), even inconsistent condom use has some benefit.
93,94
 
Nevertheless, condom use remains low in many regions and in populations similar 
to ours.  
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Condom counseling following notification of HIV-positive status  
Condom counseling is a common component of HIV post-test counseling, but the 
format varies. Whether it occurs in the context of a public health intervention or 
routine clinical care, counseling is often required following an HIV test (whether the 
test is positive or negative). The format, content, length and setting of counseling 
varies widely: sessions may be delivered individually or in groups, be didactic or 
interactive, and include demonstrations or role-playing.
95
  
 
The goal of increasing condom use, for individuals who have been recently infected, 
is to prevent subsequent transmission to partners. However, counseling is not 
always effective at increasing condom use. Although sustained increases in condom 
use in individuals receiving “enhanced” counseling (compared to more abbreviated 
programs) have been reported,
96-99
 other programs see initial success followed by 
subsequent regression to baseline levels,
100-102
 and still others find little or no effect 
of counseling interventions.
103-105
  
 
No available studies have prospectively measured condom use before and after 
HIV/STI diagnosis. Most condom counseling programs are conducted at the 
moment of HIV diagnosis, and all participants have just been given their positive 
result. When comparing condom use before and after the intervention, therefore, the 
“pre-intervention” measure of condom use is recorded after participants learn they 
are HIV-infected. Such condom use measures may be biased down (i.e., individuals 
report lower than true condom use) or up (individuals report higher than true 
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condom use) because of participants’ new knowledge of their infection status. An 
alternative design is to compare behaviors of HIV-infected individuals to a similar 
HIV-negative population to detect any differences that might be due to notification of 
HIV-positive status. Measures of condom use for these individuals may be similarly 
biased. Existing research suffers from another limitation: it has been conducted 
largely among specialized, high-risk populations (for example in the US, in 
adolescents or gay men; in international settings, in sex workers or truckers) and is 
not generalizable to the general population women in our study. Nevertheless, in the 
absence of relevant studies comparing behavior before and after notification of HIV 
positive status, below we review the existing literature on behavior change following 
STI or HIV diagnosis.  
 
Behavior change following STI infection  
Self-reported past STI in men is correlated with future risky behavior. Men generally 
report equivalent or increased risky behavior in the period following STI diagnosis. In 
a US study 25% of men had sex while infected with an STI (85% of those men 
claimed to have told their partner before sex) and 29% did not modify their behavior 
in any way following STI (e.g., no changes in condom use behavior or number of 
sex partners).
106
 French men with past STI history had significantly increased 
likelihood of engaging in high-risk unprotected sex than men who did not have a 
prior STI.
107
 In a cohort of high-risk, heterosexual, Indian men, among 56% with an 
STI history at baseline, the likelihood of visiting a sex worker increased during the 
 
 
19 
follow-up period. However this group also reported more consistent condom use 
with both sex workers and other partners.
108
 
 
Past STI in US adolescents is associated with increased STI prevention knowledge 
and temporary abstinence, but also high rates of multiple partnerships and repeat 
STI. Adolescents with prior STI initially report reduced risky behaviors, but over time, 
sexual risk taking resumes to or increases beyond baseline levels. Although they 
may temporarily abstain from sex and, when initially resuming sexual activity, report 
higher condom use than uninfected peers,
109-111
 adolescents previously infected with 
STIs also report higher rates of multiple partnerships and subsequent 
infections.
82,109,110,112-115
 Condom use rates that were higher early in follow-up are 
typically not sustained,
102,110,114 
and other high risk behaviors, such as sex while 
intoxicated and unprotected sex with multiple partners, are higher among those with 
a previous STI.
114
 Of interest, participants with past STI often report better STI 
prevention knowledge than those without prior STI.
114
  
 
Adult women with past STI have increased condom use but also increased risk of 
subsequent STI. As with men and adolescents, self-reported STI history in women is 
associated with higher future condom use.
99,107,116,117
 Women with prior STI also 
experience higher rates of subsequent STI,
118,119
 although STI rates were lower in 
women receiving a specialized condom promotion intervention compared to the 
standard counseling program.
99
 In one of few studies in international settings, South 
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African women recruited from STI clinics reported continuing sexual activity, 92% 
without condoms, despite knowledge of current infection.
120
  
 
Behavior change following HIV infection  
Risky behavior in HIV-positive people is more difficult to characterize generally than 
behavior in STI-positive individuals. While many continue to engage in high-risk 
behavior, others adopt higher levels of condom use. No study has prospectively 
measured condom use before and after HIV acquisition. 
 
A meta-analysis of HIV counseling covering studies conducted between 1985 and 
1997 found that the benefits of counseling were more apparent in those testing HIV-
positive than those testing negative.
121
 HIV-positive people (and HIV serodiscordant 
couples) generally increased their condom use, whereas HIV-negative people 
generally did not change condom use behavior. HIV-positive people generally had 
lower STI rates following counseling, whereas HIV-negative individuals had STI 
rates similar to uncounseled populations.
121 
Another review found a significant 
increase in condom use and abstinence over time in HIV-positive women receiving 
counseling, particularly when a woman’s partner was also counseled. In general, the 
authors report that HIV-positive individuals are more likely to use condoms than 
HIV-negative individuals.
122
 
 
Some HIV-positive women reduce risk behaviors, but others become pregnant and 
acquire STIs after HIV seroconversion. Several studies from international settings 
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characterized the risk behaviors of HIV-positive women, with varying results. In 
some areas (Democratic Republic of Congo and Kenya), HIV counseling and testing 
had little impact on fertility rates in HIV-positive women,
123,124
 whereas HIV-positive 
Ugandan women had lower pregnancy rates than their HIV-negative peers.
125,126
 
HIV-positive Rwandan women were more likely to use condoms, and had lower GC 
prevalence, than HIV-negative women.
127
 In the US, substantial numbers of HIV-
positive women become pregnant and experience STIs after HIV diagnosis.
128,129
  
 
In the US, many HIV-positive individuals continue to engage in high-risk behavior. 
Both adolescents and adults continued to engage in risky behavior following HIV 
diagnosis,
130
 with high proportions experiencing STI in the period after 
seroconverting to HIV.
131,132
 Although HIV-positive people receiving counseling may 
have higher rates of condom self-efficacy and report fewer acts of unprotected sex, 
they do not report changes in their number of sex partners.
133
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TABLE 2.2. Misclassification of male circumcision status. 
 
Reference Sensitivity Specificity Study location 
  
Classification by men* 
    
77
 44% 83% United States 
134
 51% 96% United States 
135
 66% 79% United States 
32,136
 88% 99% 
Spain, Colombia, Brazil, Thailand, 
Philippines 
137
 89% 84% Panama, Costa Rica, Colombia, Mexico 
78
 92% 68% United States 
138
 94% 72% Tanzania 
139
 96% 94% Kenya 
30
 98% 99% Australia 
31
 98% 99% United States 
45
 ~100% ~100% Kenya 
140
 47% 93% United States 
  
Classification by women about their partners* 
    
79
 86% 94% Rwanda 
81
 70%
†
 79%
†
 United States 
80
 92% 94% United States 
Gray R 92% 97% Uganda 
   
*    All reports except Gray R (unpublished) compare to clinician exam as the gold standard. The 
Gray report compares women’s reports to men’s reports.  
†     
Clinician classification of “uncircumcised” - glans 2/3 to completely covered by foreskin; 
“circumcised” - foreskin completely absent or foreskin covered up to 2/3 of glans. 
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FIGURE 2.1. Relationship between HIV prevalence
141
 and MC prevalence
16,17
 in 
Sub-Saharan Africa.
15
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ANG: Angola 
BEN: Benin 
BOT: Botswana 
BUF: Burkina Faso 
BUR: Burundi 
CAM: Cameroon 
CAR: Central African Republic 
CHA: Chad 
CON: The Congo 
DJI: Djibouti 
DRC: Democratic Republic of the Congo 
EQA: Equatorial Guinea 
ERI: Eritrea 
ETH: Ethiopia 
GAB: Gabon 
GAM: Gambia 
GHA: Ghana 
GUB: Guinea Bissau 
GUI: Guinea 
IVO: Cote d’Ivoire 
KEN: Kenya 
LES: Lesotho 
LIB: Liberia 
MAL: Mali 
MAU: Mauritania 
MAW: Malawi 
MOZ: Mozambique 
NAM: Namibia 
NIA: Nigeria 
NIR: Niger 
RWA: Rwanda 
SEN: Senegal 
SIE: Sierra Leone 
SOA: South Africa 
SOM: Somalia 
SUD: Sudan 
SWA: Swaziland 
TAN: Tanzania 
TOG: Togo 
UGA: Uganda 
ZAM: Zambia 
ZIM: Zimbabwe
  
 
 
 
 
 
 
 
CHAPTER 3: METHODS 
 
We conducted these secondary analyses using data from the “Hormonal 
Contraception and the Risk of HIV Acquisition” (HC-HIV) study (formerly HIVNET 
protocol 021). HC-HIV was a multi-center, prospective cohort study conducted in 
Uganda, Zimbabwe and Thailand, with a primary aim to evaluate the effect of low-
dose combined hormonal contraceptive pills (COCs) and injectable depot 
medroxyprogesterone acetate (DMPA) on women’s risk of HIV acquisition. 
Additional data for Aim 2 analyses came from an ancillary study of HC-HIV, the 
“Effect of Hormonal Contraception on HIV Genital Shedding and Disease 
Progression among Women with Primary HIV Infection” (GS) study. The purpose of 
GS is to examine the effect of hormonal contraception on HIV genital shedding and 
disease progression among women who became HIV-infected during HC-HIV. 
 
Data sources 
 
HC-HIV study 
 
Study population 
HIV-seronegative women (n=6,109) were recruited over a 34-month period from 
November 1999 through September 2002. To answer the primary study aim, users 
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of COCs and DMPA and women not using hormonal contraception (HC) were 
recruited in approximately equal numbers in each country.  
 
Study setting 
Women were enrolled from three sites in Kampala, Uganda; four sites in Harare and 
Chitungwiza, Zimbabwe; and seven sites in Chiang Mai, Khon Kaen, Hat Yai, and 
Bangkok, Thailand. Initially, women were recruited from family planning (FP) and 
maternal-child health (MCH) clinics; however, owing to low initial HIV incidence rates 
in the family planning population in Uganda, and especially in Thailand, recruitment 
was expanded to include higher-risk populations (see below). These participants 
were referred through STI clinics or primary health care clinics when women 
presented with STI symptoms. They included military wives and those referred 
through sex worker networks. These women met all study eligibility criteria. 
 
Eligibility criteria 
To enroll in HC-HIV, women had to be 18 to 35 years of age; sexually active (at 
least three sex acts in the past three months); if parous, at least 4.5 months post-
partum; HIV seronegative; and using a) low dose COCs for at least three months 
with intention to continue for the next 12 months, or, b) DMPA for at least three 
months with intention to continue for the next 12 months, or, c) a non-hormonal 
method or no contraceptive method.  
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Exclusion criteria 
Women were excluded who were pregnant or intending to become pregnant in the 
next 12 months; used an intrauterine device (IUD) in the last month; used any HC 
besides COCs or DMPA in the previous three months; used COCs in the last three 
months or DMPA in the previous six months (and no longer using that method); 
injected illicit drugs within the previous three months; received a blood transfusion 
within the previous three months; had a hysterectomy; had an abortion 
(spontaneous or induced) within the previous month; or was participating or had 
previously participated in an HIV vaccine trial. 
 
Procedures 
At screening, women were assessed for study eligibility, consented, and specimens 
were collected for HIV, syphilis and HSV-2 testing. Women returned within 15 days 
for their test results, and if HIV-negative and otherwise eligible, were invited to join 
the study. At the baseline visit they were reconsented, interviewed about their 
reproductive, contraceptive and sexual behavior, and examined. Specimens were 
collected to diagnose vaginal and cervical infections.  
 
Follow-up clinic procedures were similar to those conducted at baseline, and visits 
were conducted approximately every three months for up to two years.  
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Recruitment and retention 
Most participants (n=5,223; 85%) were recruited during routine visits to FP or MCH 
clinics. Women were approached by staff in the waiting room and given information 
about the study. A prescreening instrument of six questions was used to determine 
preliminary eligibility, including questions about age and contraceptive method. 
Interested women were then invited to participate in formal screening for the study. 
 
Some higher risk participants (n=886; 15%) were referred through STI clinics, 
primary health care clinics if they presented with STI symptoms, or sex worker 
networks. Staff attended these clinics and spoke to potentially eligible women as 
they waited to be seen by clinicians. Staff invited these women to return to a FP or 
MCH clinic routinely used for HC-HIV study procedures.  
 
If a participant failed to appear for a scheduled visit, staff attempted to contact her 
by telephone, mail and through home visits. Overall retention was 92% at 24 months 
and was very similar across contraceptive groups. 
 
Data collection 
All behavioral data were recorded on paper forms during face-to-face interviews 
conducted by trained interviewers with individual participants. All clinical exam data 
were recorded on paper forms by trained clinicians during and following physical 
exams. Testing for some reproductive tract infections (including trichomonal 
infection, bacterial vaginosis (BV) and candidiasis) was performed at the clinic using 
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microscopy. In Uganda and Thailand, study clinicians carried out this testing and 
recorded the results on paper forms. In Zimbabwe, microscopy was performed by 
on-site laboratory technicians. Other diagnostic assays were performed off-site by 
laboratory personnel; clinicians then transcribed biomedical data from laboratory 
source documents onto paper forms. 
   
At screening for HC-HIV, the short Screening Eligibility form was administered by 
staff to each potential participant to determine her eligibility. This form assessed 
inclusion and exclusion criteria, and also recorded demographic data to enable 
investigators to accurately characterize the screened population. At screening 
women provided blood samples for HIV, HSV-2 and syphilis testing, and the results 
were recorded on the Screening Laboratory Results form.  
 
Women returned to the clinic within 15 days for their enrollment visit. At this visit, 
staff administered the Baseline Questionnaire form, which collected demographic 
information, current and past contraceptive use, and current and past sexual 
behavior. Participants underwent a pelvic exam, and clinicians recorded their 
observations and the results of on-site diagnostic procedures for Tv, candidiasis and 
bacterial vaginosis on the Physical Exam form. Cervical swabs were collected to test 
for chlamydial and gonococcal infection, and the results of the laboratory assays 
that identified these infections were later recorded on the Laboratory Results form.  
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Women were followed every 12 weeks for approximately two years (median follow-
up was 22 months). At follow-up visits, participants were interviewed using the 
Follow-up Questionnaire form, which again captured information on contraceptive 
use, sexual behavior, partner’s sexual behavior, and STI symptoms. They 
underwent a physical exam, and clinicians again recorded their observations and 
diagnoses for Tv, candidasis and bacterial vaginosis on the Physical Exam form. 
Serum and cervical samples for testing for HIV, Ct and GC were collected, and the 
results of these assays were recorded on the Laboratory Results form.  
 
HIV/STI diagnosis 
 
HIV 
At screening and each follow-up visit, 10-15 cubic centimeters of blood was 
collected from each woman for HIV testing. Serum was separated and stored in 2 ml 
aliquots. Aliquots not used for immediate serologic testing were stored at -80˚C. A 
participant was considered HIV-positive if she was positive on a combination of two 
enzyme-linked immunosorbent assays (ELISA) and/or rapid tests and Western blot 
positive, or, polymerase chain reaction (PCR) positive. If the initial ELISA was 
positive, a rapid test was used for confirmation testing. Negative or indeterminate 
results were resolved by using a second rapid test. Western Blots were performed 
on women who had two positive results on ELISA or rapid tests. In the case of 
continued indeterminate results, HIV PCR testing was performed as the final arbiter 
of HIV status. 
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When an incident HIV infection was identified, the participant was called back for a 
retest to rule out labeling errors. If she had a positive ELISA or rapid test at that visit 
she was considered HIV-positive. Serial testing with HIV PCR using stored 
specimens from prior visits was conducted to accurately date incident HIV 
infections. 
 
Serum specimens were processed and stored at the local site laboratory. Diagnostic 
testing was performed at the local site laboratory or at a certified laboratory within 
each country. 
 
Neisseria gonorrhoeae and Chlamydia trachomatis 
Endocervical specimens were collected at enrollment and at all follow-up visits for 
diagnosis of both gonococcal and chlamydial infection. After collection, swabs were 
vigorously agitated in a collection tube for up to 15 seconds and then discarded. 
Samples were processed using PCR (AMPLICOR® Ct/NG Test, Roche Diagnostics, 
Somerville, NJ, USA). This assay detects both Ct and GC infections using a single 
swab. For Ct, optical density (OD) >0.8 was positive, and for GC, OD>2.5 was 
positive. Negative results were indicated for OD <0.2 for Ct, and OD <0.2 for GC. 
Testing was repeated for results in the “gray zone” (for Ct: OD of 0.2–0.8; for GC, 
OD of 0.2–2.5). 
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As with serum samples, cervical specimens were processed and stored at the local 
laboratory for each site. Diagnostic testing was also performed at the local site 
laboratory or at a certified laboratory within each country. 
 
Trichomonas vaginalis 
At enrollment and each follow-up visit, clinicians touched a cotton swab to the lateral 
vaginal wall and then suspended it in 1-2 ml sterile saline to make a wet mount. The 
fluid was examined under low (10x) and high (40-45x) magnification for the 
presence of motile flagellated trichomonads. Identification of trichomonads indicated 
positive Tv infection. 
 
HIV/STI diagnosis and partner notification 
At HC-HIV screening, women who tested positive for HIV were ineligible for the 
study. They were given intensive post-test counseling and referred both to a support 
group for HIV-positive women and for additional counseling services. Women were 
told that their partners could receive free HIV testing and counseling at the clinic. All 
HIV-positive women were made aware of relevant research studies for which they 
might be eligible.  
 
If an enrolled participant tested positive for HIV during the HC-HIV study, she was 
called back for a redraw visit (10-21 days after the initial test) to rule out labeling 
errors. At the redraw visit, counselors informed the woman that her HIV test 
appeared positive, but that further confirmatory tests were needed. A definitive 
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result was given to the participant 1-2 weeks after the redraw visit. Women were told 
that their partners could receive free HIV testing and counseling at the clinic. 
Women who were confirmed HIV-positive were told they were no longer eligible to 
participate in HC-HIV, but they were invited to join GS (in Uganda and Zimbabwe) 
(see below).  
 
Testing for curable STIs was not performed at screening. If participants tested 
positive for curable STIs at enrollment or during HC-HIV follow-up, they were given 
treatment and told that their partners could also receive STI testing and treatment 
from the study. Women were again counseled about STIs and condom use, and 
participants were given condoms to take home if desired.  
 
Treatment of curable STIs varied across study sites and during the follow-up period. 
Data were not collected on whether women’s partners were tested or treated. 
 
Data management 
Data entry for HC-HIV was completed using the DataFax data management system. 
DataFax breaks up each fax into individual pages, corrects any misalignment 
problems, flips pages faxed upside down, identifies which participant each page 
belongs to, reads the data, enters the data into the study database, and stores all 
pages as electronic images. DataFax generally reduces the amount of data cleaning 
required after study termination, since it automates much of the clerical work 
involved in data entry and speeds necessary corrections to incorrect data.  
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At the end of each day, all forms completed by study staff were sent to the Project 
Office at each site. Each site faxed completed paper forms over ordinary phone 
lines. Data management staff used DataFax validation tools (such as logic and 
range checks) to review all pages received, complete data entry and flag any 
problems (e.g., missing or potentially incorrect data). At least two people viewed 
every form received to ensure accuracy and data quality. On a pre-established 
schedule, a quality control (QC) report was generated and faxed back to each site. 
The QC reports showed the follow-up status of all screened and enrolled 
participants at that site and identified any problems flagged during the data review. 
Sites were asked to correct any problems and refax the corrected form pages. 
When received, the data management staff reviewed them again and updated the 
study database. 
 
The data were managed by the Statistical Center for HIV/AIDS Research & 
Prevention (SCHARP), part of the Public Health Sciences Division of the Fred 
Hutchinson Cancer Research Center in Seattle, WA. SCHARP personnel provided a 
complete copy of the HC-HIV dataset for these analyses.  
 
Main findings  
HC-HIV’s main findings have been reported previously.
142
 Neither COCs nor DMPA 
was associated with increased risk of HIV acquisition among women (HR for COCs: 
0.99, 95% CI: 0.69 to 1.42; HR for DMPA: 1.25, 95% CI: 0.89 to 1.78).  
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GS study 
 
Eligibility criteria for GS were similar to those for HC-HIV. In addition, all GS 
participants were HIV-infected, and women who were pregnant or using an IUD 
were permitted to enroll. 
 
Procedures 
All women at the Zimbabwe and Uganda HC-HIV sites, who experienced HIV 
infection during follow-up, were invited to enroll in GS. GS participants who joined 
soon after HIV diagnosis had multiple early follow-up visits (at 2, 4 and 8 weeks after 
GS study entry); follow-up visits then took place, as in HC-HIV, approximately every 
three months. At each GS visit the standard HC-HIV questionnaires were 
administered to collect information on reproductive variables, contraceptive 
exposure and recent sexual behavior. A pelvic exam was performed, and blood, 
cervical and vaginal specimens collected for STI diagnosis. Study participants 
continued to receive their chosen contraceptive method.  
 
Unless otherwise specified, procedures for GS were the same as described above 
for HC-HIV. 
 
Data management 
Data management for GS was conducted by SCHARP through July 2003; Family 
Health International (FHI) subsequently assumed management of the GS data. 
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Following each visit, questionnaire, physical exam and laboratory forms were 
checked at the site for accuracy and completeness.  They were then transmitted to 
the Data Management division at FHI, where data were entered and QC and data 
management procedures were conducted using the ClinTrials software system 
(Clintrials Research Inc., Cary, NC). FHI personnel provided a complete copy of all 
relevant GS data for these analyses. 
 
Analytic overview  
Our analyses answered two secondary research questions: 1) is primary partner’s 
circumcision status associated with women’s risk of acquiring HIV or three treatable 
STIs (Ct, GC or Tv)? and 2) is notification of HIV-positive status associated with 
changes in participants’ self-reported condom use over the short- or longer-term?  
 
Aim 1 analyses 
 
Using the HC-HIV data, Aim 1 examined MC as a risk factor for women’s acquisition 
of HIV, Ct, GC, and Tv. 
 
Analysis population  
Aim 1 analyses were performed on enrolled women: 
1) completing at least one follow-up visit with valid HIV/STI results (depending 
on the outcome under investigation) 
2) reporting a primary partner and subsequently answering questions about that 
partner’s circumcision status 
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3) returning for follow-up within 28 months of enrollment  
4) using one or more contraceptive methods (COCs, DMPA or non-hormonal 
methods) under study for the primary objective of HC-HIV (women using 
exclusively non-study methods were excluded). 
 
For the analysis of MC and HIV, women were censored after becoming infected with 
HIV. Only four HIV infections occurred in the Thai cohort during follow-up, so Thai 
women (n=1,578) were excluded from HIV analyses but not from STI analyses. For 
the STI analyses, women were censored after their first infection with the individual 
STI under investigation.  
 
Outcome assessments 
Each model for Aim 1 used a dichotomous outcome coded as 0 (no incident 
infection) and 1 (incident infection). Infections were diagnosed as described above. 
 
HIV: Incident HIV infection was defined as the first positive HIV result in a previously 
HIV-negative woman.  
Chlamydia trachomatis: Initial incident Ct infection was defined as the first positive 
Ct result at a follow-up visit in a woman who was Ct-negative at all previous visits; 
or, the first positive Ct result in a woman who previously had missing or 
indeterminate Ct results at a follow-up visit, followed by a confirmed negative result, 
prior to her first positive Ct (see example in Table 3.1). 
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Neisseria gonorrhoeae: Initial incident GC infection was defined as the first positive 
GC result at a follow-up visit in a woman who was GC-negative at all previous visits; 
or, the first positive GC result in a woman who previously had missing or 
indeterminate GC results at a follow-up visit, followed by a confirmed negative 
result, prior to her first positive GC (Table 3.1). 
 
Trichomonas vaginalis: Initial incident Tv infection was defined as the first positive 
Tv result at a follow-up visit in a woman who was Tv-negative at all previous visits; 
or, the first positive Tv result in a woman who previously had missing or 
indeterminate Tv results at a follow-up visit, followed by a confirmed negative result, 
prior to the first positive Tv (Table 3.1). 
 
Any STI: Initial incident STI infection was defined as the first positive STI result (Ct, 
GC or Tv) at a follow-up visit in a woman who was STI-negative at all previous visits; 
or, the first positive STI result in a woman who previously had missing or 
indeterminate STI results at a follow-up visit, followed by confirmed negative results 
for all three infections, prior to the positive STI. 
 
Time: Person-time was calculated as the number of months from the baseline visit 
to either a) the date of HIV or STI diagnosis in those experiencing infection, or b) the 
date of last study contact for women lost to follow-up (censored), or c) the date of 
the last study visit for participants remaining infection-free for their full study 
duration. A small group of women had extended follow-up, however, because follow-
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up officially ended at the visit following 24 months, we censored follow-up time from 
all participants after 28 months. 
 
Exposure 
All five analyses (for outcomes HIV, Ct, GC, Tv, and any STI) for Aim 1 used the 
same exposure variable: primary partner’s circumcision status as reported by 
women. In preliminary univariable and bivariable analyses, MC was treated as a 
three-level variable coded 0 (not circumcised), 1 (circumcised) and 2 (women does 
not know partner’s circumcision status). In multivariable models for HIV, follow-up 
intervals where women reported they did not know their partner’s circumcision status 
were excluded, and MC was treated dichotomously: 0 (not circumcised) and 1 
(circumcised). In multivariable models for the STI outcomes, MC was modeled as a 
three-level variable: not circumcised, circumcised, and of unknown circumcision 
status (coded as two indicator variables with uncircumcised partners as the common 
referent group). 
 
At baseline and each follow-up visit, women were asked first “In the last three 
months, have you had a primary partner? By primary partner, we mean your 
husband, someone with whom you live, or your boyfriend...” Those women who 
answered yes were later asked, “Is this partner circumcised?” This question was 
repeated at each follow-up visit. If women’s primary partner changed, the 
circumcision status of the new partner was recorded; MC was therefore permitted to 
vary over the follow-up period. 
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Covariables 
A large number of covariables were assessed through preliminary univariable, 
bivariable and simple multivariable analyses prior to the modeling phase of the 
analysis.  
 
Covariables fell into several categories: demographic (age, marital status, 
education, occupation, ethnicity, other socioeconomic (SES) factors), reproductive 
characteristics (contraceptive history, age at coital debut, gravidity, use of vaginal 
drying products), risk behavior (alcohol use, number of sex partners, new sex 
partners, sex work, STI history during the study, sexual concurrency, condom use), 
and risk characteristics (reported by women) of the primary partner (his age, 
HIV/STI status, STI symptoms, occupation, time spent away from home, 
concurrency).  
 
Variables considered for inclusion in multivariable models are shown in Figure 3.1, 
depicting a Directed Acyclic Graph (DAG).
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 To simplify the graphic, only 
relationships between the exposure, outcome and each covariable have been 
drawn; additional relationships between covariables are present but not depicted. Of 
note, using DAG methodology, only religion (unmeasured), ethnicity (measured) and 
SES could confound the main association. Nevertheless, each covariable in the 
DAG was evaluated in turn since they had been included in previous analyses of 
this and similar research questions.  
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Unmeasured variables 
Some variables identified as confounders in previous studies of circumcision and 
HIV/STI (in men) were not measured in this study and so were not included in our 
analyses. These include: 
1. men’s age at circumcision: some evidence suggests that the age at which 
circumcision is performed changes its possible protective effect against 
HIV
144,145
  
2. “degree” of circumcision in partners
146
 
3. men’s hygiene practices
147-149
 
4. urbanicity, mobility,
22
 and other unmeasured socioeconomic factors
150
 
5. religion
151-154
 
6. male partner’s ethnicity
153
 
 
Univariable analyses 
For all variables, we first evaluated the frequency of missing data and identified 
outliers.  We assessed the mean, median, standard deviation and overall 
distribution of each continuous variable using graphical data displays. We 
considered various categorization schemes for continuous variables, and developed 
meaningful cut-points using previous literature, critical percentiles, and based on the 
distribution of the data. We inspected the frequencies of all dichotomous and 
categorical variables.  
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Bivariable analyses 
The relationships between each variable and the main exposure, and between each 
variable and each outcome, were evaluated using unadjusted Cox proportional 
hazards models.
155
  
 
Multivariable analyses 
 
Preliminary assessments of effect measure modification and confounding 
We hypothesized that HC use, pregnancy, age, country, and source population 
(e.g., recruitment from FP/MCH clinics vs. higher-risk settings) could modify the 
circumcision-HIV/STI association (the “main association”). To evaluate them as 
possible effect measure modifiers (EMMs), we compared the magnitude and 
precision of the main association within each level of each possible modifying 
covariable in turn;
156
 we also made qualitative assessments about the importance of 
presenting stratified estimates of effect for each variable. For each potential EMM, 
we ran a simple Cox model containing partner’s circumcision status, HIV/STI, the 
potential EMM, and an interaction term between MC and the possible EMM. We 
examined the p-value for the interaction term, and interpreted values lower than 
α=0.10 as evidence of substantial heterogeneity in the stratum-specific measures of 
effect.
157
 For variables that appeared to be strong EMMs, we included in the starting 
multivariable model interaction terms between MC and these variables (see below).  
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Variables that were not important EMMs were assessed as potential confounders. 
For each possible confounder, we ran two simple Cox models: the first model 
containing MC, HIV/STI, and the potential confounder, and the second containing 
just MC and HIV/STI. We compared the HRs generated by the two models by taking 
the natural log of the ratio of the two estimates [ln(HRmodel with confounder/HRmodel without 
confounder)]. A result >0.05 (representing >5% change between the HRs of the two 
models) was interpreted as sufficient evidence to include the variable under 
consideration in the starting multivariable model (see below). We did not include 
variables that, based on our causal model (see Figure 3.1) we expected to be on the 
causal pathway between MC and women’s risk of HIV/STI. 
143
 
 
Multivariable modeling 
We used five separate extended Cox proportional hazards models
155,158
 to estimate 
adjusted hazard ratios (HRs) describing the effect of MC on: 
 
1. time to HIV infection 
2. time to first infection with Ct 
3. time to first infection with GC 
4. time to first infection with Tv 
5. time to first infection with any STI 
 
The data were structured in the “counting process” format, one record per visit and 
multiple records per woman. Proportional hazards models can accommodate 
  45 
multiple records per person, and the counting process format permits proper 
analysis of both time-independent and time-varying covariates.
159
 Extended Cox 
models use a robust variance estimator to adjust for non-independence resulting 
from multiple visits per participant.
160
  
 
Before beginning the model-building phase of the analysis, we created a preliminary 
dataset with one record per woman to assess the proportional hazards assumption 
(PHA) required for Cox regression models. Each woman’s record contained her 
values for those variables that do not vary with time, and aggregate, over-time 
summary values for time-dependent variables (mean, summary, or median, 
depending on the variable). We created interactions between each variable (both 
time-independent and time-dependent) and continuous or categorical follow-up time, 
and examined log(-log(s(t)) plots and log h(t) to determine if strata of the covariable 
were proportional over time. We used Cox tests
161
 to evaluate the significance of the 
coefficient of the interaction term. If the interaction was not statistically significant at 
α=0.05, we concluded that that the PHA was not violated for that variable. If the 
coefficient was significant, the interaction between the covariable and continuous 
time was included in the full model. A covariable×time interaction term permits the 
influence of the covariable to vary with time, thereby relaxing the PHA. Ties were 
accommodated using the Efron method.
162
 
 
The full model for each outcome consisted of the dichotomized exposure (MC), 
interaction terms between MC and variables determined to be EMMs, interaction 
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terms for covariables with time for covariables that violated the PHA, and all 
covariables that confounded or modified the MC association.  
 
We presented unadjusted and adjusted HRs for the effect of MC on women’s risk of 
HIV and STIs, and Kaplan-Meier curves
163
 depicting HIV and STI-free survival time 
by the MC status of women’s primary partner. 
 
In general terms, the full model for HIV is represented by the following equation:  
hx(t) = h0(t) × e
β1(MC) + β2(covariableK) + β3(covariableK × time) + β4(MC × covariableK) 
 
where  
t =  continuous time (i.e., hx(t) is the hazard at time t when X=x)  
h0(t) =  baseline hazard function 
MC =  MC status of women’s primary partner, coded 0 
(uncircumcised) or 1 (circumcised)  
covariableK
a
 =  representing all covariables (time-varying or time-
independent) that were confounders or EMMs as determined 
in preliminary multivariable analysis  
covariableK
a
 × time = interaction term between covariableK and time, for any 
covariableK that violated the PHA; time coded continuously  
                         
a
  The term CovariableK stands in for the set of individual terms, one for each variable that may 
modify of confound the main measure of effect, that were included in the full model. 
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MC × covariableK
a
 =  representing all interaction terms between covariables and the 
main exposure 
 
To assess EMM using multivariable models, we examined the significance of each 
MC × covariable interaction term in the starting, full model. Because of difficulty 
interpreting multiple interaction terms, we specified a priori that the final model could 
have a maximum of one interaction term; multiple HRs for the effect of MC (one for 
each stratum of the interacting variable) were presented in the final estimates.  
  
We then used a manual backward elimination approach with a 10% change-in-
estimate criterion to identify which covariables confounded the main association and 
which could be removed from the model.
164
 The potential confounder with the 
weakest confounding effect in preliminary assessments was dropped first. The HR 
for the main association in the new model (excluding the dropped covariable) was 
compared quantitatively to the HR for the main association in the previous model 
(including the dropped covariable) by taking the natural log of the ratio of the 
unadjusted and adjusted estimates (ln(HRunadjusted/HRadjusted)). The impact of 
confounding was measured within strata of EMMs.  
 
A threshold of >0.10 (a higher threshold than the 0.05 used in preliminary analyses) 
constituted substantial confounding, and the covariable under consideration was 
retained as a confounder for subsequent modeling steps. If the change in the main 
association was ≤ 0.10, the covariable continued to be excluded from the model. 
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The covariable with the next smallest change-in-estimate in preliminary 
assessments was then dropped, and the process continued until all covariables had 
been assessed in this way. When all variables had been evaluated and those not 
substantially affecting the main association had been dropped, we arrived at the 
final model.  
 
Certain covariables were retained in all models based on prior literature and 
precedent, regardless of their confounding influence. These included women’s 
current contraceptive method and age.  
 
Before generating estimates of effect from the final model, we assessed the linearity 
of the log hazard for each continuous and ordinal categorical variable. Continuous or 
ordinal categorical variables that were not linear in the log hazard were 
recategorized and/or recoded and included as indicator variables.  
 
Missing data  
We did not impute missing values but proceeded with a complete-case analysis.  
 
Sensitivity analysis for Aim 1: HIV outcome 
For analyses of MC and women’s risk of incident HIV (but not other STIs), we 
conducted sensitivity analyses to evaluate the robustness of the association to 
potential misclassification of MC.
156
 Extending the methods outlined by Greenland
165
 
and Lash
166
 to Cox proportional hazards models, we “corrected” our estimates for 
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potential misclassification of MC. We used three reports of the sensitivity and 
specificity with which women classify MC (Table 2.2): two of these compared 
women’s reports of their partner’s MC status to a clinician exam,
79,80
 and the third 
compared women’s reports to men’s reports (R. Gray, unpublished data). Intervals 
where women reported that they did not know their partners’ circumcision status 
were excluded from sensitivity analyses. We carried out the corrections in two steps, 
separately for each sensitivity-specificity pair.  
 
First, using the circumcision prevalences (in our cohort) from Zimbabwe (9.4%) and 
Uganda (35.9%), and the reported sensitivity and specificity of women’s 
classification from the three reports (described above and in Table 2.2), we 
computed the two probabilities that a participant’s report about her partner was 
inaccurate: either, that a man was truly circumcised, although his partner reported 
he was uncircumcised, or that a man was truly uncircumcised, although his partner 
reported he was circumcised. These probabilities were computed separately for the 
Ugandan and Zimbabwean cohorts, because the prevalence of circumcision (and 
presumably the likelihood of misclassification) varied by country. Second, using 
these derived probabilities, we randomly reclassified participants’ partner’s 
circumcision status 2,500 times to create 2,500 corrected datasets. From each 
reclassified dataset, we computed corrected unadjusted and adjusted HRs. For 
each sensitivity-specificity pair, we reported the median, 2.5
th
 and 97.5
th
 percentiles 
of the 2,500 simulations.   
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Sensitivity analysis for Aim 1: STI outcomes 
Our analyses evaluated the effect of circumcision status of the primary partner only 
on women’s risk of acquisition of HIV and three STIs. Since some women reported 
multiple sexual partnerships during follow-up, our observed associations may reflect 
a mixture of the effects of primary and non-primary partners’ circumcision status. For 
the STI analyses only, we conducted a simple sensitivity analysis by removing from 
the analysis all follow-up time where women reported multiple sexual partners. We 
then refit the unadjusted and adjusted models (using the same set of adjustment 
variables as in the main analysis) to determine whether the associations between 
MC and women’s STI risk changed. 
 
Limitations of analysis of Aim 1 
Aim 1 analyses had several limitations. First, as noted above, the use of women’s 
reports of their partners’ MC status likely introduced misclassification in the MC 
measure. We attempted to characterize the extent and influence of the 
misclassification through sensitivity analysis. Second, a criticism of previous 
circumcision studies was that they suffered from unmeasured confounding by 
religion. We also lacked data on religion, although we used ethnicity as a proxy for 
religion (three categories in Zimbabwe and seven in Uganda),
b
 and adjusting for 
these variables had no substantial effect on the parameter estimates. In addition, 
because religion and ethnicity do not affect HIV risk directly but are themselves 
                         
b  Shona, Ndebele, and other in Zimbabwe; Muganda, Munyankole, Mukiga, Munyoro, Mutoro, 
Munyarwanda, and other in Uganda. 
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proxies for behavioral characteristics related to disease acquisition, and we 
measured these behaviors directly, we expect this bias to be minimized.  
 
Fourth, as with any laboratory procedure, methods to diagnose HIV, Ct, GC and Tv 
are not 100% sensitive and 100% specific. Because HIV acquisition was the primary 
endpoint for HC-HIV, a variety of assays were used to detect infection (depending 
on the study visit and result of initial testing): 1) enzyme-linked immunosorbent 
assays (ELISA) [Recombigen HIV-1/HIV-2 (Cambridge Biotech, Galway, Ireland), 
Organon Vironostika (Organon Teknika, Durham, North Carolina, USA), Abbott 
Murex (Abbott Park, Illinois, USA), Sanofi (Sanofi Diagnostics Pasteur, Redmond, 
Washington, USA)]; 2) HIV rapid tests [HIV SAV1 or SAV2 (Savyon Diagnostics, 
Ashdod, Israel), Capillus HIV-1/HIV-2 (Trinity Biotech USA, Jamestown, New York, 
USA) or Determine (Abbott)]; 3) PCR (Amplicor HIV-1 DNA test, version 1.5, Roche 
Diagnostics, Branchburg, New Jersey, USA); and 4) Western blot (BioRad, 
Hercules, California, USA). All positive HIV results were checked and confirmed to 
rule out errors, and we expect misclassification of HIV status to be negligible. The 
AMPLICOR Ct/NG test, which has published sensitivity and specificity of 91.7% and 
99.7%, respectively, for Ct
167
 and 92.4% and 99.5%, respectively, for GC,
168
 has 
been criticized for cross-reactivity with nonpathogenic neisseriae strains,
169-171
 
leading to higher false-positive rates for GC than test characteristics suggest. 
Microscopy (wet mount), the diagnostic method for trichomonas, has poor sensitivity 
(49%-67%) but nearly perfect specificity (often cited as 100%) compared to PCR.
172-
175
 We anticipate that misclassification of Tv status is nondifferential with respect to 
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the exposure, suggesting the that observed effect estimates for Tv may be biased 
toward the null.
156
 
 
Although not a limitation in our analytic techniques, we note that male circumcision 
is not a woman-controlled method of infection prevention. Ultimately, for women to 
better control their risk of HIV/STI acquisition, they need tools directly within their 
own control that do not require negotiation with a male partner. MC has many 
advantages: a one-time surgery may confer lifetime benefit, it may be administered 
in infancy, the surgery is simple and inexpensive, and it is not coitally-dependent. 
Nevertheless, women cannot insist that their partners be circumcised. Many women 
will remain in a vulnerable situation parallel to what they now experience when their 
partners refuse to use male condoms.  
 
Finally, we note that we were unable to distinguish whether any association between 
MC and women’s risk of HIV or STIs represents a change in risk of transmission to 
women (i.e., MC affects male infectivity) or a change in the likelihood of the male 
partner being infected initially due to his circumcision status (followed by subsequent 
transmission to a susceptible female partner). Although a quantification of these two 
distinct effects of MC would be ideal, we believe our analysis, capturing the total 
effect of MC on women’s HIV/STI risk, makes a valuable contribution to 
understanding this exposure.  
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Halloran and Struchiner
176
 describe three measurable effects for exposure-disease 
scenarios where the likelihood of experiencing an outcome is dependent on the 
prevalence of people who have already experienced it: the direct effect, indirect 
effect, and overall effect. Our analysis captured the overall effect of MC circumcision 
on women’s HIV/STI risk. As with a vaccine, male circumcision may permit a man to 
avoid initial infection (primary transmission; Halloran and Struchiner’s “direct effect”), 
thereby breaking a link in the disease transmission chain, and subsequently 
reducing or eliminating the risk of infection in his sex partners (secondary 
transmission; Halloran and Struchiner’s “indirect effect”). The total effect, a lower 
population prevalence of infection (Halloran and Struchiner’s “overall effect”), is the 
combination of the direct and indirect effects.  
 
Strengths of analysis of Aim 1 
Despite the limitations described above, HC-HIV provided an excellent opportunity 
to characterize women’s risk of HIV/STI associated with partner’s circumcision 
status. HC-HIV was a very large, prospective, multicenter study. It was conducted in 
a population of largely monogamous women, making the findings widely 
generalizable. The investigators collected prospective data on multiple outcomes, 
permitting extensive investigation of the influence of men’s circumcision status on 
women’s disease risk. Unlike many studies in which similar analyses have been 
done, we were able to adjust for many potential confounders. Precise dating of 
incident HIV infections (by PCR, using previously-collected and stored specimens) 
to pinpoint the timing of HIV acquisition allowed more accurate time-to-event 
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analyses. Measurement of hormonal contraception variables is believed to be highly 
accurate, since methods were provided by the study (with all details recorded on 
study forms when dispensed), and self-reported DMPA injection history could be 
compared to clinician documentation.    
 
Aim 2 analyses 
 
Aim 2 seeks to examine changes in women’s self-reported condom use a short and 
longer time period after notification of HIV-positive status (Figure 3.2). We merged 
data collected during HC-HIV with data collected during GS.    
 
Short-term comparison  
Our first analysis examined short term changes in participants’ self-reported condom 
use. For women who experienced HIV infection during HC-HIV, we selected one 
HC-HIV visit two to six months prior to notification of HIV-positive status and one GS 
visit two to six months after HIV diagnosis. To capture any secular changes in 
condom use that may have taken place over the follow-up period, we also included 
visits from women who did not become HIV-infected during HC-HIV. From all HC-
HIV visits contributed by uninfected women, we randomly selected one “anchor” visit 
(see below), then chose corresponding visits two to six months before and two to six 
months after the anchor visit. From all uninfected women with visits within the 
specified timeframe, we randomly selected a sample in an approximate 4:1 ratio 
with HIV-infected women.  
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Long-term comparison 
Second, we examined changes in self-reported condom use over a longer time 
period.  For women who experienced HIV infection during HC-HIV, we again 
selected one HC-HIV visit two to six months prior to notification of HIV-positive 
status, but we paired it with one GS visit twelve to sixteen months after HIV 
diagnosis. For women remaining uninfected, we chose corresponding visits two to 
six months before the randomly-selected anchor visit and twelve to sixteen months 
after the anchor visit. We again randomly selected a sample of uninfected women in 
an approximate 4:1 ratio with HIV-infected participants. Although the same number 
of uninfected women were selected for short- and long-term analyses (n=650 for 
each analysis), because of the random selection process, uninfected participants 
included in the long-term analysis were not necessarily the same uninfected women 
as in the short-term analysis.  
 
Visit selection 
The goal of visit selection for each analysis was to have a pair of observations for 
each participant, with one “before” and one “after” measure. To be included in these 
analyses, HIV-infected women had to have GS visits within the specified timeframes 
(within six months of the redraw visit (see below) for the short-term analysis and at 
least 12 months after the redraw visit for the long-term analysis); uninfected women 
had to participate in HC-HIV long enough for comparison measures to be captured 
(at least two months after their randomly-assigned anchor visit for the short-term 
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analysis and at least 12 months after their anchor visit for the long-term analysis). 
When participants (HIV-infected or HIV-uninfected) contributed more than one visit 
within the specified timeframe, we chose the visit with non-missing data on condom 
use that was closest to the beginning of the window (e.g. closer to two months than 
six months, or closer to twelve months than sixteen months).  
 
As described earlier, because of low HIV incidence in Thailand, Thai women 
(n=1,578) were excluded from Aim 2 analyses.  
 
Random selection of anchor visits for uninfected participants 
Uninfected comparison participants for the short- and long-term analyses were 
randomly selected from the 4,226 HC-HIV participants who did not become HIV 
infected during HC-HIV. Using SAS’s random number generator, we assigned each 
visit contributed by uninfected women a random number RAND. We sorted the 
dataset by participant ID and then RAND, so that all observations were ordered in 
truly random order within participant-specific clusters. We then assigned the first 
visit for each woman to be her “anchor” visit. We confirmed that for the full cohort of 
uninfected women, the duration of study participation prior to the anchor visit was 
roughly uniform. We then selected an HC-HIV visit two to six months prior to the 
anchor visit, two to six months after the anchor visit (for the short-term analysis), and 
12 to 16 months after the anchor visit (for the long-term analysis). For the subset of 
participants who had “before” and “after” visits within the specified time frames, we 
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used the RAND value of the anchor visit to randomly select 650 uninfected 
participants for each analysis. 
 
Outcome measure: Number of sex acts not protected by male condoms in a typical 
month in the last three months 
At each follow-up visit, during both the HC-HIV and GS studies, participants were 
asked: “In the last three months, in a typical month, how many times did you have 
sex?” and “In the last three months, in a typical month, how many times did your 
partner use a male condom during sex with you?” Women answered these 
questions about all partners, separately for primary and other partners. The number 
of sex acts not protected by male condoms in a typical month was calculated as the 
total number of sex acts with all partners minus the total number of sex acts where 
male condoms were used.  
 
Exposure measure: notification of HIV-positive status 
Participants received HIV tests at every follow-up visit in HC-HIV using a 
combination of two enzyme-linked immunosorbent assays or rapid tests. Positive 
results were confirmed by Western Blot or HIV polymerase chain reaction tests. 
Following a positive result, the participant was called back for a redraw visit (typically 
10-21 days after the initial test) to rule out labeling errors. At the redraw visit, 
counselors informed the woman that her HIV test appeared positive, but that further 
confirmatory tests were needed. A definitive result was given to the participant 1-2 
weeks after the redraw visit. For this analysis, we used the date of the redraw visit, 
  58 
when women were first told they were likely infected with HIV, as the date of 
notification of HIV-positive status. 
   
Covariables 
Figure 3.3 depict the variables evaluated as confounders for Aim 2.  
 
Data analysis for Aim 2 
 
Univariable analyses 
Univariable analyses were conducted as described above for Aim 1.  
 
Bivariable analyses 
Bivariable analyses were conducted in a similar manner to that described above for 
Aim 1, using unadjusted zero-inflated negative binomial (ZINB) models (see below) 
rather than Cox models.  
 
Multivariable models 
Because our outcome (number of unprotected sex acts) was a count, we considered 
and compared the fit of regression models using the Poisson, negative binomial, 
zero-inflated Poisson and ZINB distributions (Figure 3.4).
177-179
 ZINB provided the 
best fit, and we subsequently used ZINB models to examine the change, with 95% 
CIs, in the number of unprotected sex acts in a typical month.  
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ZINB models follow a two-step process. The first is a logistic model that predicts a 
binary outcome: zero vs. more than zero in the value of the count. The second 
process is a negative binomial model including those observations with a count 
value more than zero; it predicts the value of the non-zero count. Parameter 
estimates are produced for both model steps. The logistic and negative binomial 
processes can have the same or different sets of predictor variables.  
 
For these data, effect estimates from the logistic procedure can be interpreted as an 
odds ratio (OR) comparing the odds of having no unprotected sex acts in a typical 
month after HIV diagnosis (for women experiencing HIV infection) or anchor visit (for 
uninfected women), with the odds of having no unprotected sex acts in a typical 
month beforehand. A measure less than 1.0 indicates that the odds of having no 
unprotected acts in a typical month have declined after HIV diagnosis or anchor 
visit, compared to the odds of having no unprotected acts in a typical month 
beforehand; a measure greater than 1.0 indicates that the odds of having no 
unprotected acts have increased. 
 
Interpretation of effect estimates from the negative binomial portion of the model 
change depending on whether an offset variable is included (inclusion of the offset 
does not affect interpretation of the logistic portion of the model). We ran each ZINB 
model without and then with an offset variable capturing the total number of sex acts 
in a typical month. Without an offset, effect estimates from the negative binomial 
portion of the model represent the relative change in the number of unprotected acts 
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in a typical month after HIV diagnosis or anchor visit, compared to number of 
unprotected acts in a typical month beforehand. A measure less than 1.0 indicates 
that the number of unprotected sex acts in a typical month has declined; a measure 
greater than 1.0 indicates that the number of unprotected acts has increased.  
 
With the offset variable, the measure of effect from the negative binomial portion of 
the model can be interpreted as a relative change in the proportion of unprotected 
acts in a typical month. Interpretation is otherwise similar: a measure less than 1.0 
indicates that the proportion of all acts where male condoms were not used in a 
typical month has declined; a measure greater than 1.0 indicates that the proportion 
of acts where male condoms were not used has increased. 
 
We used a robust variance estimator to account for non-independence resulting 
from repeated measures on individual participants.
160
 
 
We examined participants’ demographic characteristics, reproductive factors and 
sexual behavior for their confounding influence on the association between 
notification of HIV-positive status and condom use (see Figure 3.3). We included in 
each starting multivariable model all factors that were associated with HIV-positive 
status or condom use.   
 
Because each model already produced four important interpretable measures of 
effect (logistic process for HIV-infected women, logistic process for uninfected 
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participants, negative binomial process for HIV-infected women, negative binomial 
process for uninfected participants), we did not consider any variables as EMMs for 
Aim 2. 
 
To construct final models, we used a manual, backward elimination, change-in-
estimate strategy.
164
 One at a time, we removed covariates from the starting model; 
if removal changed the association with number of unprotected sex acts by less than 
10%, a given covariate was not retained. We designated models as “final” when the 
remaining covariates confounded the main association or were retained for a priori 
considerations (age).  
 
Any covariable that confounded the estimate for HIV-infected participants or for 
uninfected women, in short- or long-term analyses, in the logistic or negative 
binomial portions of the model, in a model with or without the offset variable, was 
included in the final adjustment set for all other analyses. 
To generate separate effect estimates for HIV-infected and uninfected participants, 
we used three independent variables in both the logistic and negative binomial 
portions of the ZINB model: HIV, coded 0 for women who remained HIV-negative 
throughout HC-HIV and 1 for women who became HIV-infected while participating in 
HC-HIV; TIMEPOINT, coded 0 for visits prior to HIV diagnosis or anchor visit and 1 
for visits after; and a product interaction term between TIMEPOINT and HIV. 
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The full models for Aim 2 are represented by the following equations (models fit 
simultaneously):  
 
Logistic process 
logit(unprotect=0)  = α0 + α1(timepoint) + α2(HIV) + α3(timepoint × HIV) + 
α4(covariableK) 
 
Negative binomial process 
log(unprotect=X|X>0)  = β0 + β1(timepoint) + β2(HIV) + β3(timepoint × HIV) + 
β4(covariableK) [offset = log(sexfreq)] 
where 
unprotect:  number of sex acts in a typical month in the last three months 
where condoms were not used, coded continuously 
timepoint:  dichotomous variable coded 0 at the pre-diagnosis visit and 1 
at the post-diagnosis visit 
HIV:  dichotomous variable distinguishing women who experienced 
HIV during the study (coded 1) from women who did not 
(coded 0) 
timepoint × HIV:  interaction term between TIMEPOINT and HIV, coded 1 for 
subjects who experienced HIV and for the post-diagnosis visit, 
0 otherwise 
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covariableK
c
:  represents all covariables (time-varying or static) that were 
confounders in preliminary analysis 
sexfreq: total number of sex acts in a typical month in the last three 
months, coded continuously, used as the offset variable 
 
Two example interpretations of the models above:  
• e
(α1+ α3):
 
the odds of HIV-infected women reporting no unprotected acts in a 
typical month post-infection compared to the odds of HIV-infected women 
reporting no unprotected acts in a typical month pre-infection.  
• eβ
1
:
 
the number of unprotected acts in a typical month reported by uninfected 
women after the anchor visit, compared to the number of unprotected acts 
reported by uninfected women before the anchor visit.
 
[This interpretation is 
for the model without an offset variable; with offset variable, the comparison 
is about the proportion, rather than absolute number, of sex acts in a typical 
month where condoms were not used]. 
 
Missing data  
Missing data was addressed as described for Aim 1. We again conducted a 
complete case analysis.  
 
                         
c  The term CovariableK represents the set of individual terms, one for each variable that may modify 
of confound the main measure of effect, that will be included in the full model; for example, age, 
education, ethnicity, employment, etc. 
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Limitations of Aim 2 analyses  
This analysis has several limitations. First, several authors have noted potential 
methodologic flaws in using self-reported behavioral data, rather than biomarkers, to 
evaluate changes in risky sexual behavior.
180,181
 Although self-reported sexual 
behavior is generally believed to be accurate,
182,183
 we could not validate women’s 
self-reports of condom use.  
 
Additional biases may operate that could reduce the validity of condom use 
measures. Particularly in the short-term comparison, women who have recently 
experienced HIV may feel embarrassed or guilty about their recent infection. This 
may prompt them to report higher or lower condom use than is accurate. In addition, 
although all women received condom counseling during follow-up, counselors 
delivering positive HIV test results may give those participants more directed or 
intensive condom counseling than they deliver to women testing negative. As a 
result, women with recent infection may have greater behavior change not because 
of HIV diagnosis itself, but due to the more intensive counseling they receive from 
counselors.  
 
Although we captured data about the frequency of condom use in several ways, we 
lacked an evaluation of the correctness of use. Correctness is necessarily correlated 
with the degree of protection that condoms can provide, and matters of proper 
timing, placement, and other procedural issues of condom use will also influence 
their efficacy.
181  
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Similar to the limitation of Aim 1 described above, we note that women are not the 
final decision-makers in matters concerning use of male condoms. Even if women 
are motivated after HIV diagnosis to increase condom use, they may face resistance 
from male partners. 
 
 
Strengths of analysis of Aim 2 
No studies in the existing literature have used a prospective design to evaluate 
changes in risky behavior following HIV or STI diagnosis. Women in HC-HIV were 
asked identical questions both before and after HIV infection, allowing directly 
comparable condom use information from periods months prior to diagnosis with 
periods months, and more than one year, following diagnosis. Most previous 
prospective studies had short follow-up periods, many of three months or less. In 
HC-HIV, median follow-up time was 22 months. Cohort retention was also high, with 
92% of Ugandan and Zimbabwean participants retained for 24 months. As with the 
analysis in Aim 1, findings from the women in our cohort are widely generalizable to 
women living in high-HIV prevalence regions in sub-Saharan Africa.  
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TABLE 3.1. Sample incident infection coding. 
  
 
 
Visit Result Incident Infection? 
Baseline Positive N/A 
2 Positive Not counted 
3 Negative No 
4 Negative No 
5 Positive Yes 
6 Negative No 
7 Positive Yes 
8 Positive Not counted 
9 Positive Not counted 
10 Indeterminate or missing Not counted 
11 Negative No 
12 Indeterminate or missing Not counted 
13 Positive Not counted 
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Partner’s 
circumcision status 
Incident HIV, 
Ct, GC, Tv 
? 
Parity/gravidity 
Education 
Age 
Ethnicity/partner’s ethnicity 
Religion* 
Occupation/partner’s occupation 
Marital status 
Condom use 
Alcohol use/partner’s alcohol use 
 
Past STI 
# sex partners 
Contraceptive use / study arm 
Age at coital debut 
Partner’s current STI status* 
Paid sex  
Sexual concurrency/partner’s sexual concurrency 
Use of vaginal drying agents/douching 
SES factors* 
Men’s hygiene practices* 
Men’s age at circumcision* 
“Degree” of circumcision* 
* unmeasured 
Source population 
Country 
Pregnancy 
FIGURE 3.1. Causal model for male circumcision and women’s risk of acquisition of 
HIV/STI (Aim 1). 
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Notification of HIV-
positive status 
Change in 
condom use 
? 
Education 
Age 
Ethnicity 
Religion* 
Occupation 
Cohabitation status 
Alcohol use 
Past STI 
Number / new sex partners 
Age at coital debut 
Sexual concurrency 
 
Paid sex practices 
Partner’s current HIV/STI status* 
Contraceptive use / study arm  
Disclosure of HIV status to partner* 
 
Parity/gravidity 
SES factors* 
Partner characteristics (circumcision status, nights away 
from home, hygiene practices, sexual concurrency, 
occupation, alcohol use) 
Use of vaginal drying agents 
Baseline condom use 
*unmeasured 
Pregnancy  
Country  
Source population 
FIGURE 3.3. Causal model for notification of HIV-positive status and changes in 
condom use (Aim 2). 
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CHAPTER 4: MEN’S CIRCUMCISION STATUS AND WOMEN’S RISK OF HIV 
ACQUISITION IN ZIMBABWE AND UGANDA 
 
ABSTRACT 
 
Objective: To assess whether male circumcision (MC) of the primary sex partner is 
associated with women’s risk of HIV acquisition. 
 
Design: Data were analyzed from 4,417 Ugandan and Zimbabwean women who 
participated in a prospective cohort study of hormonal contraception and HIV 
acquisition. Most participants were recruited from family planning clinics, although 
some in Uganda were referred from higher-risk settings such as sexually transmitted 
disease clinics. 
 
Methods: Using Cox proportional hazards models, time to HIV infection was 
compared for women with circumcised vs. uncircumcised primary partners. Possible 
misclassification of MC was assessed using sensitivity analyses. 
 
Results: Most women (73.8%) reported an uncircumcised primary partner at 
baseline, whereas 22.5% had circumcised partners and 3.8% had partners with 
unknown circumcision status. During follow-up, 210 women acquired HIV (167, 34, 
and 9 women whose primary partners were uncircumcised, circumcised, or of 
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unknown circumcision status, respectively). The unadjusted hazard ratio (HR) 
comparing women with circumcised partners to those with uncircumcised partners 
was 0.69 (95% CI: 0.48-0.99). After stratification by referral population and 
adjustment for other factors, any suggested protection offered by MC was limited to 
“high-risk” Ugandans (HR: 0.16 (95% CI: 0.02-1.25), whereas MC had little effect on 
HIV acquisition in “low-risk” Ugandans (HR: 1.33, 95% CI: 0.72-2.47) or 
Zimbabweans (HR: 1.12, 95% CI: 0.65-1.91).  Results were largely unchanged after 
sensitivity analyses evaluating possible misclassification of reported MC. 
 
Conclusions: Although MC appeared protective against women’s HIV acquisition in 
unadjusted analyses, after adjustment male circumcision was not associated with 
women’s HIV risk among most participants.  
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INTRODUCTION 
 
Male circumcision (MC), a surgical procedure involving cutting and removal of the 
foreskin, has received increased attention in recent years due to its potential to 
reduce men’s risk of HIV acquisition. Although a preponderance of evidence 
suggests that circumcised men have lower risk of acquiring HIV than uncircumcised 
men,
19-22,24,25
 the subsequent HIV risk in their female sex partners is not known. 
When compared to women with uncircumcised partners, women with circumcised 
partners have been found to have lower,
64,66-70 
higher,
72
and approximately equal risk 
of HIV acquisition.
71
 
 
Several biologic mechanisms have been proposed through which a woman’s HIV 
risk may be altered by her partner’s circumcision status. Uncircumcised men may 
have a higher efficiency of transmitting HIV (and possibly other sexually transmitted 
pathogens), because the foreskin is a repository for shed cells and a hospitable 
environment for microorganism growth.
7
 In HIV-infected individuals, male foreskins 
have substantially higher levels of HIV DNA than female ectocervices; in contrast, 
HIV DNA from the keratinized outer surface of the foreskin is below the limits of 
detection.
74
 When the inner layer of the foreskin becomes exteriorized during 
intercourse, uncircumcised men may expose their partners to both a greater 
infectious “surface area” and an increased number of infectious organisms, thereby 
increasing the risk of transmission.
184
 Finally, MC may have no direct effect on the 
transmissibility of HIV from infected men to susceptible women, but if circumcision 
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reduces men’s HIV risk, women partnered with circumcised men may be less likely 
to be exposed to HIV.  
 
Using data from a multi-site, prospective cohort study of incident HIV infection in 
Uganda and Zimbabwe, we examined the effect of MC on women’s risk of HIV 
acquisition.   
 
METHODS 
 
We conducted a secondary analysis using data from the Hormonal Contraception 
and Risk of HIV Acquisition (HC-HIV) Study, a multi-site, prospective cohort study 
assessing the effect of hormonal contraception on HIV acquisition among women. 
The methods are described briefly below and have been published elsewhere.
142
  
 
Study setting and population  
HC-HIV recruited women from Uganda, Zimbabwe, and Thailand. Thai women were 
excluded from this analysis because of very low HIV incidence.  
 
From November 1999 through September 2002, women were enrolled from three 
sites in Uganda and four sites in Zimbabwe. Eligible women were 18-35 years of 
age; HIV-seronegative; sexually active (≥  three sex acts in the past three months); 
and users of either combined oral contraceptive pills (COCs), injectable depot 
medroxyprogesterone acetate (DMPA), or a non-hormonal or no contraceptive 
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method. Contraceptive group was not randomly assigned; women were already 
using their chosen contraceptive method at enrollment. All Zimbabwean and most 
Ugandan participants were recruited from family planning and maternal-child health 
clinics. Owing to low initial HIV incidence rates among Ugandan participants, 
recruitment in Uganda was expanded to include referrals from “high-risk” 
populations, such as sexually transmitted disease clinic patients, sex workers and 
military wives. 
 
Data collection  
We restricted the analysis to women in Zimbabwe and Uganda who completed at 
least one follow-up visit with valid HIV results and answered a question about their 
primary partner’s circumcision status (see below). Follow-up officially ended at the 
first visit following 24 months. We censored follow-up time after 28 months for a 
small number of women with extended follow-up.   
 
At enrollment and each follow-up visit, women received structured, face-to-face 
interviews about their reproductive, contraceptive and sexual behavior and physical 
exams with specimen collection. Visits were conducted approximately every three 
months.  
 
At enrollment, participants were asked whether they had a primary sexual partner 
(“In the last three months, have you had a primary partner? By primary partner, I 
mean your husband, someone with whom you live, or your boyfriend.”). They 
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answered several questions about that partner, including his circumcision status. At 
subsequent visits, women were asked whether their primary partner had changed. 
Participants with a new primary partner were asked about that partner’s circumcision 
status, and therefore partner’s circumcision status was time-varying in our analysis. 
We did not collect MC data for non-primary partners. 
 
Women were considered HIV-infected if positive on a combination of two enzyme-
linked immunosorbent assays or rapid tests. Positive HIV results were confirmed by 
Western Blot or HIV polymerase chain reaction (PCR) tests. We conducted serial 
testing on stored specimens using PCR to accurately date incident HIV infections.  
 
Statistical analyses 
All statistical analyses were performed using SAS (Version 9.1.3, SAS Institute, 
Cary, NC). 
 
Using extended Cox proportional hazards models, we estimated unadjusted and 
adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) to describe the 
effect of primary partner’s circumcision status on women’s time to HIV infection. 
Person-time was calculated as time from enrollment to either the date of HIV 
infection or the date of the last study visit for women remaining uninfected.  
 
We hypothesized that the association between MC and women’s HIV risk could vary 
by four factors previously associated with incident HIV in women: age, pregnancy, 
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contraceptive group, and population (a composite variable capturing both country 
and referral population, and representing recruitment from family planning clinics in 
Uganda vs. higher-risk settings in Uganda vs. family planning clinics in Zimbabwe). 
Product-interaction terms were constructed between MC and each of these 
variables; interaction terms with p<0.10 were included in the preliminary 
multivariable model.
157
 We also examined participants’ demographic characteristics, 
reproductive factors, sexual behavior, and partner characteristics (as reported by 
women) for their confounding influence on the MC effect measure. We included in 
the preliminary multivariate model those variables that were associated with MC or 
HIV acquisition in simple Cox models. To assess the proportional hazards 
assumption, we created interactions between each variable and continuous time; we 
used survival plots and Cox tests for statistical evaluation.
161
 For variables violating 
this assumption, we included the time-interaction variables in the preliminary 
multivariate model. 
 
We then used a manual, change-in-estimate backward elimination strategy to 
remove one at a time those variables which did not confound the association 
between MC and women’s HIV risk.
161
 Covariates were not retained if their removal 
changed the main association by less than 10% overall or in any stratum of any 
interacting variable.
164,185
  
 
  78 
Sensitivity analysis 
We examined the robustness of the observed association between MC and 
women’s risk of HIV acquisition using sensitivity analysis (comparable to the 
methods of Lash and Silliman
166
). Because MC status was reported by women, we 
assessed the influence of misclassification of men’s circumcision status on the 
observed HRs. 
 
Using three reports of the sensitivity and specificity with which women classify MC, 
we corrected our estimates of the association between MC and women’s HIV risk. 
Two of these compare women’s reports of their partner’s circumcision status to a 
clinician exam,
79,80
 and the third compares women’s reports to men’s reports (R. 
Gray, unpublished data). Women who did not know their partners’ circumcision 
status were excluded. We carried out these corrections in two steps, separately for 
each sensitivity-specificity pair.  
 
First, using the circumcision prevalences in these data from Zimbabwe (9.4%) and 
Uganda (35.9%), and the reported sensitivity and specificity of women’s 
classification, we computed the two probabilities that a participant’s report about her 
partner was inaccurate: either, that a man was truly circumcised, although his 
partner reported he was uncircumcised, or that a man was truly uncircumcised, 
although his partner reported he was circumcised. These probabilities were 
computed separately for the Ugandan and Zimbabwean cohorts, because the 
prevalence of circumcision (and presumably the likelihood of misclassification) 
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varied by country. Second, using these derived probabilities, we randomly 
reclassified participants’ partner’s circumcision status 2,500 times to create 2,500 
corrected datasets. From each reclassified dataset, we computed corrected 
unadjusted and adjusted HRs. For each sensitivity-specificity pair, we report the 
median, 2.5
th
 and 97.5
th
 percentiles of the 2,500 simulations.   
 
Ethical approval 
All participants provided written informed consent prior to study entry. HC-HIV was 
approved by ethics committees of collaborating institutions. This secondary analysis 
received ethical approval from the University of North Carolina at Chapel Hill.  
 
RESULTS 
 
HC-HIV enrolled 4,531 participants from Uganda and Zimbabwe. We excluded 114 
women: 80 who did not return for follow-up; 14 who returned for the first time more 
than 28 months after enrollment, and were therefore censored; 12 who used 
exclusively non-study contraceptive methods, and 8 with missing data on 
circumcision status at every follow-up visit. (Thirteen women missing the MC status 
of their primary partner at baseline, but with valid MC data later in follow-up, were 
excluded from Table 4.1 but included in longitudinal analyses). This analysis 
includes 4,417 women (393 “high-risk” Ugandans (8.9%), 1,793 “low-risk” Ugandans 
(40.6%), and 2,231 Zimbabweans (50.5%)) who together contributed 7,559 person-
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years (PY) of follow-up. The mean interval between follow-up visits was 0.24 years 
(2.9 months).  
 
Baseline population characteristics (Table 4.1) 
Among 4,404 women providing MC status of their primary partner at baseline, most 
(n=3,249, 73.8%) had uncircumcised partners, whereas 22.5% (n= 989) had 
circumcised partners and 3.8% (n=166) did not know their partner’s circumcision 
status. Circumcision was more common among partners of Ugandan (35.9%) than 
Zimbabwean women (9.4%). Nearly all women (98.2%) who did not know whether 
their partner was circumcised came from Zimbabwe.  
 
Users of COCs, DMPA, and non-hormonal methods were roughly balanced among 
circumcised and uncircumcised groups (p=0.65). Women with circumcised partners 
had somewhat less education than those with uncircumcised partners (8.6 vs. 9.3 
years, p<0.01), a lower mean age at coital debut (16.8 vs. 17.7 years, p<0.01), a 
higher mean number of lifetime sex partners (4.8 vs. 2.7 partners, p<0.01), and a 
higher mean number of nights the primary partner was away from home in the last 
month (9.1 vs. 6.1 nights, p<0.01).   
 
Follow-up 
Over the follow-up period, participants with circumcised partners contributed 1,672 
PY in 6,942 (22.4%) follow-up intervals; women with uncircumcised partners 
contributed 5,631 PY in 22,977 (74.1%) follow-up intervals; and those who did not 
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know their partner’s circumcision status contributed 256 PY in 1,076 (3.5%) follow-
up intervals. Changes in partnerships where the new partner had a different 
circumcision status than the previous partner were relatively rare, reported by 243 
women (5.5%) at some point over the follow-up period. Partnership changes were 
more common among women in Uganda than those in Zimbabwe: 8.7% of high-risk 
Ugandans and 9.1% of low-risk Ugandans reported at least one partnership change 
over follow-up, compared to 2.0% of Zimbabweans.  
 
Similar to the baseline findings, women partnered with circumcised men reported 
somewhat riskier sexual behavior during follow-up visits. Women with circumcised 
partners were more likely to self-report a sexually transmitted infection (STI) (6.4% 
vs. 4.4% of follow-up intervals, p<0.01) or STI symptoms (25.6% vs. 19.6% of 
follow-up intervals, p<0.01), and to have a risky sexual partner – a man with STI 
symptoms, other sex partners, or who was HIV-positive – (23.1% vs. 13.6% of 
follow-up intervals, p<0.01). Although more women with circumcised partners 
reported never using condoms since the last visit (64.1% vs. 50.2% of follow-up 
intervals, p<0.01), they had a lower mean number of unprotected acts per month 
(8.6 vs. 9.3, P<0.01) than women with uncircumcised partners. 
 
At enrollment and throughout follow-up, observed differences in risk behavior 
between women with circumcised partners and uncircumcised partners are largely 
due to the reported differences in risk behavior between women in Uganda and 
Zimbabwe. Women in Uganda both reported generally riskier behavior and were 
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more likely to report a circumcised primary partner (36%), whereas women in 
Zimbabwe generally reported less risky behavior, and fewer had circumcised 
primary partners (9%).  
 
HIV acquisition 
HIV infection occurred in 210 women during the follow-up period (34, 167 and 9 HIV 
seroconversions in women with partners who were circumcised, uncircumcised, and 
of unknown circumcision status, respectively). Unadjusted HIV incidence rates were 
2.03 per 100 PY (95% CI: 1.35-2.72) among those with circumcised partners, 2.97 
per 100 PY (95% CI: 2.52-3.42) in women with uncircumcised partners, and 3.51 
per 100 PY (95% CI: 1.22-5.81) in women who did not know their partner’s 
circumcision status.  
 
Unadjusted and adjusted multivariate models 
The unadjusted Cox proportional hazard model for time to HIV seroconversion 
indicated that women with circumcised partners had a reduced HIV risk compared to 
women with uncircumcised partners (HR: 0.69, 95% CI: 0.48-0.99) (Table 4.2). The 
Kaplan-Meier plot shows similar results (log-rank p=0.06, Figure 4.1). After 
adjustment for age, age at coital debut, contraceptive method, husband’s 
employment status, education level, and number of sex partners in the previous 
three months, the protective effect of male circumcision weakened (HR: 0.78, 95% 
CI: 0.53-1.14 (Table 4.2)). After further adjustment for population (high-risk 
Ugandans, low-risk Ugandans, and Zimbabweans), the association disappeared 
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(HR: 1.03, 95% CI: 0.69, 1.53 (Table 4.2)).  We saw no evidence of confounding by 
other demographic factors, including ethnicity, or other sexual behavior variables, 
including STI coinfection (capturing infection with Chlamydia trachomatis (Ct), 
Neisseria gonorrhoeae (GC), Trichomonas vaginalis (Tv), or herpes simplex virus 
type 2 (HSV-2)). 
 
Because we detected substantial heterogeneity of the effect of MC on women’s HIV 
risk by population in preliminary analyses (p=0.08), we also examined Kaplan-Meier 
curves for each population subgroup (Figure 4.2).  HIV-free survival time for women 
with circumcised and uncircumcised partners was similar for both the low-risk 
Ugandan and Zimbabwean subgroups (log-rank p=0.62 and 0.39, respectively). For 
the high-risk Ugandan cohort, women with circumcised partners had better HIV-free 
survival than women with uncircumcised partners (log-rank p=0.05).  When we refit 
our unadjusted and adjusted models with a product-interaction term between MC 
and population, MC status was not significantly associated with women’s risk of HIV 
acquisition in any subgroup (high-risk Ugandans, low-risk Ugandans or 
Zimbabweans), although the point estimates varied widely (Table 4.2). The 
unadjusted estimate for high-risk Ugandans suggested protection, but was not 
statistically significant (HR: 0.26, 95% CI: 0.06-1.16), whereas there was little to no 
association between MC and women’s HIV risk in Zimbabweans (HR: 1.10, 95% CI: 
0.64-1.87) or low-risk Ugandans (HR: 1.28, 95% CI: 0.69-2.35).  All estimates were 
similar following adjustment (Table 4.2).  
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Sensitivity analyses: summary estimates 
Under three sensitivity-specificity scenarios (94% sensitivity with 89% specificity,
79
 
95% sensitivity with 92% specificity,
80
 and 92% sensitivity with 97% specificity (Ron 
Gray, unpublished data)), the overall association between MC and women’s HIV risk 
was robust to misclassification of MC status (Table 4.3). After randomly reclassifying 
circumcision status in 2,500 simulations, we saw little change in observed measures 
of effect. In all scenarios, the original point estimate fell within the 2.5
th
 and 97.5
th
 
percentiles of the corrected HRs.  
 
Sensitivity analyses: stratum-specific estimates 
Potential misclassification of MC was not influential for low-risk Ugandans or 
Zimbabweans, for whom the original estimates fell within the 2.5
th
 and 97.5
th
 
percentiles of the corrected HRs under all three misclassification scenarios (Table 
4.3). Possible misclassification of MC was more influential among high-risk Ugandan 
women. Under all three sensitivity-specificity scenarios, the median corrected HR for 
this group weakened considerably (though remained protective). In unadjusted 
analyses, the original point estimate for high-risk Ugandans fell within the 2.5
th
 and 
97.5
th
 percentiles of corrected HRs, but in the adjusted analyses for all three 
misclassification scenarios, the original estimate was not contained within the 2.5
th
 
to 97.5
th
 percentiles of the corrected HRs.  
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DISCUSSION 
 
Recent findings
19-21
 about the possible protective effect of MC against HIV 
acquisition in men have been greeted with both excitement and caution.
186-188
 
Because information about the effect of MC on women’s HIV risk could influence 
plans for MC-associated interventions, we undertook these analyses to determine 
whether MC was also associated with risk of HIV acquisition in men’s female sex 
partners.  
 
Although our unadjusted analysis agreed with two earlier prospective studies 
reporting a significant protective effect of MC on women’s risk of HIV acquisition,
64,66
 
after adjusting for demographic and behavioral factors, we did not observe a 
protective effect of MC for most women in our cohort. For a small group referred 
through high-risk settings, we found a non-significant suggestion of lower HIV risk 
for women with circumcised partners compared to those with uncircumcised 
partners.  
 
Population-level factors – for example, HIV prevalence, the pervasiveness of large 
sexual networks or concurrent sexual partnerships, the prevalence of genital ulcer 
disease, the availability of antiretroviral medications for treatment of infected 
individuals, and many other factors – play essential contextual roles in individual-
level risk of exposure and consequent infection with HIV. In this cohort, population 
(high-risk Ugandans vs. low-risk Ugandans vs. Zimbabweans) was influential in 
  86 
characterizing the association between MC and women’s HIV risk, suggesting that 
this composite variable captured otherwise unmeasured differences in participants’ 
risk of HIV.  
 
Population had a strong confounding influence. The unadjusted model indicated that 
MC was protective against women’s acquisition of HIV; when population was 
included in the multivariate models, the protective effect of MC disappeared. This is 
because Zimbabwean women, comprising the largest segment of the full cohort, 
were less likely to have circumcised partners but more likely to become HIV-infected 
during follow-up;
142
 thus the apparent protective effect of MC in the unadjusted 
estimate was actually due to the confounding influence of population.   
 
We also saw substantial heterogeneity of the MC effect according to population. 
After adjustment for sexual behavior and demographic factors, the suggested 
protective effect of MC was limited to the subgroup of women assumed to be at 
higher risk of HIV exposure (those in Uganda referred from higher risk settings), 
whereas women in both countries from family planning clinic populations saw no 
benefit from having a circumcised partner. The protection granted by MC to men is 
also hypothesized to be more pronounced for those with riskier sexual 
behavior.
24,25,189,190
   
 
Sensitivity analysis indicated that the unadjusted and adjusted associations between 
MC and women’s HIV risk in this cohort were largely robust to misclassification of 
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reported MC status. In almost all analyses, the original estimates fell within the 2.5
th
 
and 97.5
th
 percentiles of the corrected HRs, and the magnitude of the corrected 
associations was similar to the original estimates. The exception to this trend was 
the corrected estimates for high-risk Ugandans, which remained protective but 
weakened considerably; the original adjusted estimate for high-risk Ugandans did 
not fall within the 2.5
th
 and 97.5
th
 percentiles of the adjusted, corrected HR. This 
finding may indicate that the suggested protective effect of MC in this group was due 
in part to MC misclassification, or perhaps results from the small number of cases in 
that stratum (only 17 incident HIV infections overall, and only two infections among 
women with circumcised partners). In any case, possible misclassification of MC 
was more influential for high-risk Ugandans.  
 
Some women became infected with STIs (Ct, GC, Tv, or HSV-2) during the follow-
up period (data not shown). Because STI status may be affected by partner’s 
circumcision status (i.e., may lie on the causal pathway between MC and women’s 
HIV risk), we did not adjust for confounding by STI in the final multivariate model. 
Nevertheless, in preliminary analyses we assessed changes to the estimates when 
STI status (both individual STIs and a combined indicator of “any STI”) was 
included; the magnitude of the association between MC and women’s HIV risk was 
largely unchanged. Due to missing data, the precision of the estimate was affected, 
reinforcing our decision not to include STI status in our final multivariate models. 
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Our analysis has a number of limitations. HC-HIV was not designed to evaluate the 
role of MC on women’s HIV risk, and therefore we did not have some information 
that could have strengthened the analysis. For example, we did not ask about 
women’s or partners’ religion, hypothesized to be an unmeasured confounder in 
previous circumcision studies.
43
 However, adjustment for ethnicity, a proxy for 
religion (three categories in Zimbabwe and seven in Uganda),
d
 had no substantial 
effect on the parameter estimates. In addition, because religion and ethnicity do not 
affect HIV risk directly but are themselves proxies for behavioral characteristics 
related to disease acquisition, and we measured these behaviors directly, we expect 
this bias to be minimized.  
 
Women’s sexual behavior, as well as MC, were self-reported, and may suffer from 
recall and courtesy biases. We attempted to account for misclassification of MC 
using sensitivity analyses, although our sensitivity analyses corrected the HRs only 
for MC misclassification of the primary partner. Some women, particularly those 
referred from higher-risk settings, may have been exposed to other men with 
unknown circumcision status. However, women reported multiple sex partners at 
only 2.0% visits (2.8% of visits contributed by low-risk Ugandan women, 7.2% of 
visits by high-risk Ugandan women, and 0.3% of visits from Zimbabwean women). If 
this is an accurate report, bias resulting from exposure to other partners is likely to 
be minimal. Alternatively, if 2.0% is a substantial underreport, the observed HR may 
                         
d  Shona, Ndebele, and other in Zimbabwe; Muganda, Munyankole, Mukiga, Munyoro, Mutoro, 
Munyarwanda, and other in Uganda. 
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reflect a mixture of the effects of primary and non-primary partners’ circumcision 
status on women’s HIV risk.  
 
As with an effective vaccine, MC could affect the population prevalence of HIV in 
two ways. It may permit a man to avoid initial infection, breaking a link in the disease 
transmission chain, and thereby reduce or eliminate the risk of infection in his sex 
partners. It may also reduce the transmissibility of HIV from infected men to 
susceptible women. Our analysis captures the summary effects of these pathways. 
Ultimately a quantification of the distinct components of any effect of MC on 
women’s HIV risk is needed, and a prospective, HIV-serodiscordant couples study 
(HIV-positive men and HIV-negative women) is a superior design to parse out these 
effects (such a study is currently underway in Rakai, Uganda). We asked women 
about the HIV status of their partners, and attempted to conduct a subanalysis of 
the effect of MC on women’s HIV risk just among women with HIV-positive partners, 
but we had insufficient sample size to characterize this association (data not 
shown).  
 
Excitement about the possible protective benefits of MC may be appropriate. 
However, while MC may significantly reduce men’s risk of HIV acquisition, we saw 
little difference in HIV risk according to male circumcision status for most women in 
our cohort. 
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TABLE 4.2. Unadjusted and adjusted hazard ratios and 95% confidence intervals for 
HIV acquisition, comparing women with circumcised partners to women with 
uncircumcised partners, Uganda and Zimbabwe, HC-HIV, 1999-2004.   
 
 
   
* HR = hazard ratio; CI = confidence interval. 
† 
Adjusted for age, age at coital debut, contraceptive method, husband’s 
employment status, education, number of partners in the last three months, and 
including a product-interaction term between time and number of partners in the 
last three months (to relax the proportional hazards assumption). 
‡ 
Adjusted for the same covariates as Model 1, and in addition, population and a 
product-interaction term between time and population (to relax the proportional 
hazards assumption). Model 2 is not relevant for the population-specific 
estimates, because these estimates were generated using a product-interaction 
term between circumcision and population.
 Events HR* 95% CI* 
   
Summary estimates  
Unadjusted 201 0.69 0.48, 0.99 
Adjusted (Model 1)
†
 197 0.78 0.53, 1.14 
Adjusted (Model 2)
‡
 197 1.03 0.69, 1.53 
    
Estimates by country and referral population 
Unadjusted    
High-risk Ugandans 17 0.26   0.06, 1.16 
Low-risk Ugandans 43 1.28  0.69, 2.35 
Zimbabweans 141 1.10   0.64, 1.87 
Adjusted (Model 1)
†
    
High-risk Ugandans 14 0.16 0.02, 1.25 
Low-risk Ugandans 43 1.33 0.72, 2.47 
Zimbabweans 140 1.12 0.65, 1.91 
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CHAPTER 5: MEN’S CIRCUMCISION STATUS AND WOMEN’S RISK OF 
INCIDENT CHLAMYDIAL, GONOCOCCAL AND TRICHOMONAL INFECTIONS 
 
ABSTRACT 
 
Objectives: We examined associations between male circumcision (MC) and 
women’s risk of acquisition of three curable sexually transmitted infections (STIs): 
Chlamydia trachomatis (Ct), Neisseria gonorrhoeae (GC), and Trichomonas 
vaginalis (Tv).  
 
Methods: We analyzed data from a prospective cohort study on hormonal 
contraception and incident HIV and STI (HC-HIV study) among women from 
Uganda, Zimbabwe and Thailand. At enrollment and each follow-up, we collected 
endocervical swabs for polymerase chain reaction identification of gonococcal and 
chlamydial infection; trichomonal infection was diagnosed by wet mount. Women 
self-reported the circumcision status of their primary partner. Using Cox proportional 
hazards models, we compared time to STI acquisition for women according to their 
partner’s MC status. 
 
Results: Among 5,925 women (2,180 from Uganda, 2,228 from Zimbabwe, and 
1,517 from Thailand), 18.6% reported a circumcised primary partner at baseline, 
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70.8% reported an uncircumcised partner, and 9.7% did not know their partner’s 
circumcision status. During follow-up, 411, 307 and 373 participants had a first 
incident chlamydial, gonococcal or trichomonal infection, respectively. In multivariate 
analysis, after controlling for contraceptive method, age, age at coital debut, and 
country, the adjusted hazard ratios (HR) comparing women with circumcised 
partners to those with uncircumcised partners were: for Ct, HR: 1.22 (95% CI: 0.94 
to 1.59); for GC, HR: 0.93 (95% CI: 0.70 to 1.24); for Tv, HR: 1.05 (95% CI: 0.81 to 
1.37), and for the three STIs combined, HR: 1.02 (95% CI: 0.86 to 1.22).   
 
Conclusions: MC was not associated with women’s risk of acquisition of chlamydial, 
gonococcal or trichomonal infections in this cohort.  
 
 
 
 
 
 
 
 
 
 
  97 
INTRODUCTION 
 
Circumcised men appear to have lower risk of HIV acquisition than uncircumcised 
men in three randomized trials and dozens of observational studies,
19-21,24,25
 and 
prevention interventions focusing on male circumcision (MC) may soon be 
introduced worldwide. Whether MC is associated with women’s risk of acquisition of 
HIV or other sexually transmitted infections (STIs), however, has not been well-
studied. We found only two studies describing the association between MC and 
women’s STI risk. In a large community cohort study in Rakai, Uganda, women with 
circumcised partners had reduced risk of Trichomonas vaginalis (Tv), but equal risks 
of Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (Ct) when compared to 
women with uncircumcised partners.
67
 MC was strongly associated with decreased 
odds of Ct infection in female partners in one case-control couples’ study.
73
 
   
MC could affect STI risk in women if it reduced men’s risk of initial STI acquisition, 
and subsequently decreased the probability of future STI transmission to 
susceptible female partners. However, epidemiologic evidence regarding the 
association between MC and men’s risk of GC, Ct and Tv is mixed, and findings in 
several studies have been compromised by small sample sizes, poor study designs, 
selection bias, uncontrolled confounding and other validity concerns.  For 
gonococcal infection, many studies found no association between MC and men’s 
GC risk,
18,32,36-40
 although circumcised men had lower GC risk in some.
30,31,33-35
 A 
preponderance of evidence suggests no association between MC and men’s 
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infection with Ct
18,30-32,38-40,44-47
 with few exceptions.
34,41,42
 MC and Tv infection in 
men has not been investigated thoroughly. The two existing studies (one cross-
sectional
48
 and one ecologic
39
) both noted no association.  
 
Because interest is growing in MC as a promising disease prevention strategy, we 
analyzed whether MC was associated with women’s STI risk. Using data from a 
multi-site, prospective cohort study conducted in Uganda, Zimbabwe and Thailand, 
we examined the effect of MC on women’s risk of acquisition of Ct, GC and Tv. 
 
METHODS   
 
The Hormonal Contraception and Risk of HIV Acquisition (HC-HIV) study is a 
prospective cohort study with a primary objective to assess the effect of hormonal 
contraception on women’s risk of HIV acquisition. Detailed methods and main 
findings have been described elsewhere.
142
 We used the HC-HIV data to evaluate 
the association between MC and women’s STI risk.  
 
Study setting and population  
 
HC-HIV enrolled and followed women from 1999-2004. Eligible women were 18-35 
years of age; HIV-negative; sexually active; not pregnant or planning a pregnancy; 
and using oral contraceptive pills, injectable depot medroxyprogesterone acetate, or 
a non-hormonal or no contraceptive method.  
  99 
 
All Zimbabwean and most Ugandan and Thai participants were recruited from family 
planning and maternal-child health (FP/MCH) clinics. Owing to low initial HIV 
incidence rates among Ugandan and Thai women, recruitment in these countries 
was expanded to include referrals from “higher-risk” populations, such as sexually 
transmitted disease clinics, sex workers and military wives.  
 
Data collection 
 
Participants reported their reproductive and sexual behavior during face-to-face 
interviews conducted at enrollment and during follow-up visits (every 3 months for 
approximately 24 months). Women also reported the circumcision status and other 
characteristics of their primary partner. Each participant was asked at every visit 
whether she had the same primary partner as at her previous visit; the circumcision 
status of any new primary partner was recorded.  
 
At each visit we collected a single endocervical swab for polymerase chain reaction 
(PCR) identification of both gonococcal and chlamydial infection (AMPLICOR® 
Ct/NG Test, Roche Diagnostics, Somerville, NJ, USA). For Ct, optical density (OD) 
>0.8 was considered positive, and for GC, OD>2.5 was positive. Negative results 
were indicated for OD <0.2 for both Ct and GC. Testing was repeated if the results 
fell in the “gray zone” (for Ct: OD of 0.2–0.8; for GC, OD of 0.2–2.5). Trichomonas 
vaginalis was diagnosed using wet mount with examination under low (10x) and high 
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(40-45x) magnification. Identification of motile flagellated trichomonads indicated 
positive Tv infection.  
 
Statistical analyses 
 
All statistical analyses were performed using SAS (Version 9.1.3, SAS Institute, 
Cary, NC). 
 
We estimated unadjusted and adjusted hazard ratios (HRs) and 95% confidence 
intervals (CIs) for the effect of primary partner’s circumcision status on women’s 
time to first incident infection with 1) Ct; 2) GC; 3) Tv; and 4) any STI (Ct, GC or Tv). 
We used extended Cox proportional hazards models to account for both time-
independent and time-varying covariates.
159
  
 
We restricted the analysis to women who completed at least one follow-up visit with 
valid STI results and MC status of the primary sexual partner. Because of HC-HIV’s 
primary objective, women’s follow-up time was censored at the visit they were found 
to be HIV-infected. For women remaining HIV-negative, follow-up ended at the first 
visit after 24 months of participation; a small group of women (n=101) had extended 
follow-up, and we censored their follow-up time after 28 months.  
 
HC-HIV enrolled 6,109 participants. For these analyses, we excluded 184 women: 
149 never returned after enrollment; 9 returned for the first time after 28 months; 12 
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were missing the circumcision status of their primary partner at every follow-up visit; 
and 14 were missing results for Ct, GC and Tv at every follow-up visit. We 
separately analyzed each outcome from the remaining 5,925 women. Person-time 
contributed by women remaining infection-free for the full study duration was 
calculated as the number of months from enrollment to the last study visit. For 
women who acquired an STI during follow-up, person-time was calculated as the 
time from enrollment to first infection with the specific STI under investigation. For 
the combined analysis of all three STIs, women were censored after their first 
incident diagnosis with any one of the three infections.   
 
Women’s STI susceptibility is a function of a number of physiological factors (type of 
epithelium in the genital tract, resident flora and vaginal pH, cervical mucous, 
menstrual cycle phase, immunological repertoire of the individual, etc.)
6 
and 
behavioral factors (number of partners, frequency of coitus, condom use, etc.). 
Because hormonal contraception, pregnancy and age may each affect these 
factors, we hypothesized a priori that the association between MC and women’s STI 
risk could vary by these three variables. We also explored variation in the 
circumcision effect by a fourth variable, referral population (i.e., recruitment from 
FP/MCH clinics vs. higher-risk settings). We constructed product-interaction terms 
between MC and each of these variables, and included in the starting model 
interaction terms with p-values less than α=0.10.
157
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Multivariable models were constructed as described elsewhere (see Chapter 4). 
Briefly, we examined participants’ demographic characteristics, reproductive factors 
and sexual behavior; we included in preliminary multivariable models all variables 
associated with MC or incident STI. We evaluated the proportional hazards 
assumption (PHA) using Cox tests and through visual inspection of log -log plots.
161
 
For any variable violating the PHA, we created product-interaction variables with 
time to include in preliminary multivariable models. 
 
To construct final models, we used a manual, backward elimination, change-in-
estimate strategy.
164
 One at a time, we removed covariates from the preliminary, full 
model; if removal changed the MC-STI association by less than 10% overall or in 
any stratum of any interacting variable, a given covariate was not retained. We 
designated models as “final” when the remaining covariates confounded the MC-STI 
association or were retained for a priori considerations (age and contraceptive 
method).   
 
Any covariate surviving the manual backward elimination procedure for at least one 
of the four MC-STI associations was included in the adjustment set for all other 
analyses.  
 
Missing data 
Fifty-six women (0.9%) were missing the circumcision status of their primary 
partners at baseline, but subsequently provided this information during follow-up. 
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These women are excluded from descriptions of participant characteristics by 
baseline male circumcision status but included in multivariate models, which permit 
partner circumcision status to change if women change primary partners.   
 
At any follow-up visit, women missing Ct, GC or Tv results were coded as missing 
for the “any STI” analysis. Therefore, more women and more follow-up time are 
included in analyses of individual STIs than in the analysis of the three infections 
combined.  
 
Sensitivity analysis  
Our main analyses evaluated the effect of circumcision status of the primary partner 
only on women’s risk of acquisition of three STIs. Since some women reported 
multiple sexual partnerships during follow-up, our observed associations may reflect 
a mixture of the effects of primary and non-primary partners’ circumcision status. 
We conducted a simple sensitivity analysis by removing from the analysis all follow-
up time where women reported multiple sexual partners. We then refit the 
unadjusted and adjusted models (using the same set of adjustment variables as in 
the main analysis) to determine whether the associations between MC and women’s 
STI risk changed. 
 
Ethical approval 
All women enrolled in HC-HIV gave written informed consent prior to participating, 
and local ethics committees at collaborating institutions gave approval for the study. 
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The Institutional Review Board at the University of North Carolina at Chapel Hill 
approved this analysis. 
 
RESULTS 
 
Baseline characteristics  
 
The study population was comprised of women from Uganda (36.8%), Zimbabwe 
(37.6%) and Thailand (25.6%). High-risk participants from Uganda and Thailand 
made up 14.2% of the overall cohort (Table 5.1).  
 
At baseline, 18.6% of participants reported a circumcised primary partner, 70.8% 
had an uncircumcised partner, and 9.7% said they did not know whether their 
partner was circumcised (Table 5.1). Circumcision was more common among 
partners of Ugandan women (35.7%) than among partners of women from 
Zimbabwe (9.4%) or Thailand (7.4%).  Although the circumcision prevalence varied 
substantially by country, it did not vary by referral population within Uganda or 
Thailand. Participants’ had similar median age (25 years for women with 
circumcised and uncircumcised partners, and 26 years among women who did not 
know whether their partners were circumcised). The median level of education for all 
women, regardless of circumcision status of the primary partner, was 9 years. Most 
women (87.2%) cohabitated with their primary partner.  
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Women with circumcised partners reported somewhat riskier sexual behavior at 
baseline than women with uncircumcised partners or those who did not know 
whether their partners were circumcised. Participants with circumcised partners had 
a lower median age at coital debut (17 years vs. 18 for women with uncircumcised 
partners and 19 for women who did not know their partners’ circumcision status). 
Although the median number of sex partners in the last 3 months was the same for 
all groups (1 partner), women with circumcised partners had a higher mean number 
of partners (1.9 vs. 1.3 and 1.5 partners for women with uncircumcised partners and 
partners of unknown circumcision status, respectively). Similarly, each group 
reported a median of 0 nights that the primary partner was away from home in the 
last month, but women with circumcised partners had a higher mean number of 
nights when the partner was away (mean: 8.7 nights vs. 5.4 nights for women with 
uncircumcised partners and 3.8 nights for women who did not know whether their 
partner was circumcised). The majority of women (71.7% overall) reported ever 
using male condoms, including a higher proportion of women with circumcised 
partners (78.0%) than uncircumcised partners (71.5%). Fewer women who did not 
know whether their partner was circumcised reported ever using male condoms 
(58.2%).  
 
Prevalent STI at baseline was relatively rare (Table 5.1), and did not vary 
substantially by baseline MC status of the primary partner. At the enrollment visit, 
3.5% of participants were diagnosed with Ct (3.7%, 3.2% and 5.4% of women with 
partners that were circumcised, uncircumcised, and of unknown circumcision status, 
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respectively), 1.6% with GC (2.3%, 1.5% and 1.2%, respectively), and 2.6% with Tv 
(2.5%, 2.7% and 2.1%, respectively).  
 
During follow-up, 288 women reported a new primary partner with a different 
circumcision status than the previous partner: 198 partnership changes were 
reported by Ugandan women, 45 by Zimbabwean women, and 45 by Thai women. 
 
Unadjusted and adjusted multivariable models 
 
Chlamydial infection 
Infection with Ct was the most common incident STI in this cohort, with 411 women 
acquiring a new Ct infection during follow-up: 80 infections occurred in women with 
circumcised partners (unadjusted incidence rate (IR): 4.5 per 100 PY, 95% CI: 3.5 to 
5.5); 282 among participants with uncircumcised partners (IR: 3.9 per 100 PY, 95% 
CI: 3.5 to 4.4); and 49 among women who did not know whether their partner was 
circumcised (IR: 5.2 per 100 PY, 95% CI: 3.7 to 6.6) (Table 5.2).  
 
Time to Ct infection was similar for women with circumcised vs. uncircumcised 
partners (unadjusted HR: 1.13, 95% CI: 0.89 to 1.45). After adjustment for 
confounding variables that were retained in the manual backward elimination 
procedure (contraceptive method, age, age at coital debut, and country), the HR 
increased slightly to 1.22 (95% CI: 0.94 to 1.59) (Table 5.3).   
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Gonococcal infection 
Incident GC was detected in 307 participants: 66 with a circumcised primary partner 
(IR: 3.7 per 100 PY, 95% CI: 2.8 to 4.5); 224 with an uncircumcised partner (IR: 3.1 
per 100 PY, 95% CI: 2.7 to 3.5); and 17 who did not know whether their partner was 
circumcised (IR: 1.7 per 100 PY, 95% CI: 0.9-2.6) (Table 5.2).  
 
The unadjusted HR comparing time to initial GC for women with circumcised 
partners to those with uncircumcised partners was 1.18 (95% CI: 0.90 to 1.56); the 
adjusted HR was 0.93 (95% CI: 0.70 to 1.24) (Table 5.3).  
 
Trichomonal infection 
T. vaginalis occurred in 373 women during follow-up: 83 women reported 
circumcised primary partners (IR: 4.7 per 100 PY, 95% CI: 3.6 to 5.7); 278 
participants had uncircumcised partners (IR: 3.9 per 100 PY, 95% CI: 3.4 to 4.4); 
and 12 women did not know whether their partner was circumcised (IR: 1.2 per 100 
PY, 95% CI: 0.5 to 1.9) (Table 5.2).  
 
The unadjusted HR comparing time to initial Tv for women with circumcised partners 
to those with uncircumcised partners was 1.20 (95% CI: 0.94 to 1.54). After 
adjustment the HR weakened to 1.05 (95% CI: 0.81 to 1.37) (Table 5.3). 
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Any STI: Ct, GC or Tv 
Ct, GC or Tv was diagnosed in 895 women over the follow-up period: 180 women 
with circumcised partners (IR: 10.5 per 100 PY, 95% CI: 9.0 to 12.1); 648 
participants with uncircumcised partners (IR: 9.5 per 100 PY, 95% CI: 8.8 to 10.2); 
and 67 among women who did not know whether their partner was circumcised (IR: 
7.2 per 100 PY, 95% CI: 5.5 to 8.9) (Table 5.2).  
 
The unadjusted HR comparing time to initial incident STI (Ct, GC or Tv) for women 
with circumcised partners to those with uncircumcised partners was 1.12 (95% CI: 
0.95 to 1.32); the adjusted HR was 1.02 (95% CI: 0.86 to 1.22) (Table 5.3). The 
Kaplan-Meier curve of time to first incident STI (also unadjusted) shows similar 
findings: women with circumcised partners had similar time to STI as women with 
uncircumcised partners. Those who did not know their partner’s circumcision status 
appeared to have reduced risk of acquisition of any STI (log-rank p<0.01, see Figure 
5.1). 
 
Modeling results were largely unchanged when examining baseline (rather than 
time-varying) partner circumcision status. Because baseline condom use and 
baseline prevalence of GC and Tv were lower among Thai participants, we also 
examined whether restricting the analysis population to only African women affected 
our results; effect estimates were largely unchanged (data not shown).  
 
  109 
Sensitivity analysis  
When we excluded follow-up time where women reported multiple partnerships, our 
restricted datasets contained 2.5%-2.7% fewer person-years of follow-up, 
depending on the outcome. For example, the main analysis of any STI included 
9455 PYs, whereas the restricted analysis included 9222 PYs, a 2.5% reduction. 
After restriction, nearly all effect estimates were unchanged (data not shown). The 
HRs for Ct, however, strengthened somewhat in both the unadjusted (restricted HR 
for women with circumcised vs. uncircumcised partners: 1.23, 95% CI: 0.95 to 1.59) 
and adjusted models (restricted HR: 1.33, 95% CI: 1.01 to 1.75).  
 
DISCUSSION 
 
In both unadjusted and adjusted analyses, women with circumcised partners were at 
similar risk of chlamydial, gonococcal and trichomonal infections compared to 
women with uncircumcised partners. Women who did not know their partner’s 
circumcision status were at significantly lower risk of GC and Tv than women with 
uncircumcised partners in unadjusted analyses, but after controlling for other risk 
factors, these associations largely disappeared.  
 
Our findings largely agree with prior studies on MC and men’s risk of these STIs. 
The literature on men’s risk of Ct and Tv suggests no protective effect of 
circumcision (although the few studies of MC and Tv make overall conclusions 
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difficult).  Although the literature on MC and men’s risk of GC is mixed, many reports 
also suggest MC is not associated with men’s GC risk.  
 
Chlamydial, gonococcal and trichomonal infections in women, though easily cured, 
are often asymptomatic. Ct and GC particularly can have serious morbidities if left 
untreated, including pelvic inflammatory disease, ectopic pregnancy and infertility.
191
 
Since women’s access to STI treatment and care is limited in many regions, 
identifying prevention interventions that reduce the incidence of these infections is 
an important research priority worldwide.  
 
At least two mechanisms exist by which MC could affect women’s STI risk. First, MC 
may change men’s STI risk, and subsequently alter the probability that women will 
be exposed to infected men. However, as described above, no strong evidence 
supports a conclusively protective role for MC against men’s acquisition of the three 
STIs evaluated here. Second, MC may change the probability of transmission from 
infected men to susceptible women - the absence of a foreskin may alter the 
efficiency of pathogen transmission. Although Ct, GC and Tv infections in men occur 
nearly exclusively in the urethra,
192
 the foreskin is a repository for shed cells and 
secretions, and a moist, hospitable environment for pathogen growth. STI-infected, 
uncircumcised men may therefore expose their female partners to a higher 
pathogen burden than STI-infected circumcised men. Transient infectious 
organisms that do not ultimately adhere and infect exposed men may also have 
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longer viability in uncircumcised men. We found no reports comparing pathogen 
burdens in circumcised vs. uncircumcised men.  
 
Three clinical trials evaluating whether MC is protective against men’s risk of HIV 
acquisition have been stopped early because the intervention was found to have a 
strong protective effect (40-65% reductions in HIV incidence in circumcised men 
compared to uncircumcised men).
19-21
 More than 50 cohort and cross-sectional 
studies found largely similar results. Few prospective evaluations have 
characterized the effect of MC on women’s HIV risk, and the small number of 
existing studies have had mixed findings: an analysis of these HC-HIV data found 
no effect of MC on women’s HIV risk in women from FP/MCH populations (see 
Chapter 4) whereas three other prospective studies determined that women with 
circumcised partners had lower HIV risk than women partnered with uncircumcised 
men (in Tanzania
64
 and Uganda
65,66
).
 
A more recent evaluation of women in Rakai, 
Uganda found lower, but non-significant, HIV risk for women with circumcised 
partners.
67
  
 
Our analysis has a number of limitations. First, HC-HIV was not designed to 
evaluate the role of MC on women’s STI risk, and so some data that may have 
strengthened this analysis was not collected. For example, we did not ask about 
women’s or partners’ religion, hypothesized to be an unmeasured confounder in 
previous circumcision studies.
43
 In addition, an evaluation of MC and women’s risk 
of syphilis or chancroid might have been informative, since MC has been associated 
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with reduced risk of these two infections in men.
29
 Unfortunately, we did not have 
incidence data on syphilis or chancroid in our cohort. Second, women’s sexual 
behavior, as well as MC, were self-reported, and may suffer from recall and social 
desirability biases. In a previous analysis using these data to examine the effect of 
MC on women’s risk of HIV acquisition (see Chapter 4), we conducted extensive 
sensitivity analyses of potential misclassification of MC and observed little change in 
our estimates. Although not included here, we expect bias resulting from 
misclassification of MC to be similarly minimal. Finally, we did not know the STI 
status of women’s partners, which would have permitted us to characterize 
separately the effect of MC on men’s initial STI risk and the effect of MC on the STI 
transmissibility from infected men to susceptible women. Instead, our measures of 
effect capture the overall, combined effect of these two pathways. 
 
As with any laboratory procedure, methods to diagnose Ct, GC and Tv are not 
always accurate. Microscopy (wet mount), the diagnostic method for trichomonas, 
has poor sensitivity (49%-67%) but nearly perfect specificity (often cited as 100%) 
compared to PCR.
172-175
 A substudy comparing wet mount with PCR for Tv 
diagnosis, conducted among Zimbabwean and Ugandan participants at selected 
visits, found sensitivities and specificities for microscopy similar to published reports 
(B. Van der Pol, unpublished data). We anticipate that misclassification of Tv status 
would be nondifferential with respect to the exposure (i.e., not associated with MC), 
suggesting the that observed effect estimates may be biased toward the null. The 
AMPLICOR® Ct/NG test, which has published sensitivity and specificity of 91.7% 
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and 99.7%, respectively, for Ct
167
 and 92.4% and 99.5%, respectively, for GC,
168
 
has been criticized for cross-reactivity with nonpathogenic neisseriae strains,
169-171
 
leading to higher false-positive rates for GC than test characteristics would indicate. 
False-positive results are an issue of particular importance in a low-prevalence 
setting such as ours. In light of this problem, our outcome classification used the 
adjusted optical density parameters described in the methods (B. Van der Pol, 
personal communication), but some women diagnosed with GC during follow-up 
may have been misclassified.  
 
Because our main analysis evaluated only MC status of women’s primary partner, 
for women with multiple partners, the observed associations mix the effect of MC 
status of primary and non-primary partners. To address this limitation we included a 
sensitivity analysis that excluded follow-up time where women reported multiple 
partnerships; this analysis confirmed a lack of association between MC and GC or 
Tv. However, in adjusted models, monogamous women with circumcised partners 
appeared to have a significantly increased risk of incident chlamydial infection 
compared to women with uncircumcised partners. This finding disagrees with both 
existing analyses of MC and women’s Ct risk: one previous study found significant 
protection against Ct seropositivity for women with circumcised partners,
73
 and the 
other found no association between MC and women’s Ct risk.
67
 
 
MC has the potential to reduce HIV risk among millions of men, and intervention 
programs are being planned worldwide. The effect of MC on men’s STI risk is not 
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yet clear, and further research is warranted to determine whether MC also has direct 
or indirect effects on women’s STI risk. 
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FIGURE 5.1. Unadjusted Kaplan-Meier curve comparing women’s STI-free survival 
time by baseline circumcision status of the primary partner, Zimbabwe, Uganda and 
Thailand, HC-HIV, 1999-2004. 
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TABLE 5.1. Selected characteristics of women at enrollment, Uganda, Zimbabwe 
and Thailand, HC-HIV, 1999-2004. 
 
Characteristic n % 
Country and referral population   
Uganda    
Family planning/maternal-child health clinics 1790 30.2 
STD clinics, military wives, sex worker networks 390 6.6 
Thailand   
Family planning/maternal-child health clinics 1065 18.0 
STD clinics, military wives, sex worker networks 452 7.6 
Zimbabwe 2228 37.6 
Baseline circumcision status of the primary partner   
Circumcised 1100 18.6 
Uncircumcised 4195 70.8 
Don’t know 574 9.7 
Missing 56 1.0 
Baseline contraceptive method   
Combined oral contraceptive pills 2002 33.8 
Injectable depot medroxyprogesterone acetate 2075 35.0 
Non-hormonal or no contraceptive method 1848 31.2 
Prevalent STI at enrollment    
Ct 208 3.5 
GC 96 1.6 
Tv 152 2.6 
Currently cohabitate with primary partner   
Yes 5169 87.2 
No 756 12.8 
Currently employed   
Yes 3382 57.1 
No 2543 42.9 
Husband currently employed   
Yes 5671 95.7 
No 201 3.4 
Missing 53 0.9 
Male condom use ever   
Yes 4247 71.7 
No 1677 28.3 
Don’t know 1 0.02 
Sex with men other than primary partner in last 3 months   
Yes 275 4.6 
No 5649 95.3 
Missing 1 0.02 
Sex while intoxicated in last 3 months   
Yes 523 8.8 
No 5401 91.2 
Don’t know 1 0.02 
Ever exchanged sex for money or goods   
Yes 181 3.0 
No 5744 97.0 
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Characteristic Median IQR* 
   
Age (years) 25 22 to 29 
Education (years) 9 7 to 11 
Age at coital debut (years) 18 16 to 19 
Age of primary partner (years) 30 27 to 35 
Number of pregnancies 2 1 to 3 
Number of sex partners, last three months 1 1 to 1 
Number sex acts in last 30 days with primary partner 9 4 to 16 
Nights primary partner away in last 30 days 0 0 to 7 
 * IQR = interquartile range 
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TABLE 5.3. Unadjusted and adjusted hazard ratios and 95% confidence intervals for 
CT, GC and TV, Uganda, Zimbabwe and Thailand, HC-HIV, 1999-2004. 
 
circumcised v.  
uncircumcised partners 
partners of unknown 
circumcision status v. 
uncircumcised  
Outcome Events 
HR    (95% CI) HR    95% CI 
Ct        
Unadjusted 411 1.13 (0.89, 1.45) 1.29 (0.95, 1.74) 
Adjusted* 411 1.22 (0.94, 1.59) 0.94 (0.68, 1.30) 
        
GC        
Unadjusted 307 1.18 (0.90, 1.56) 0.55 (0.34, 0.90) 
Adjusted* 307 0.93 (0.70, 1.24) 0.95 (0.56, 1.60) 
        
Tv        
Unadjusted 373 1.20 (0.94, 1.54) 0.31 (0.17, 0.55) 
Adjusted* 368 1.05 (0.81, 1.37) 0.69 (0.38, 1.25) 
        
Any STI        
Unadjusted 895 1.12 (0.95, 1.32) 0.74 (0.58, 0.95) 
Adjusted* 890 1.02 (0.86, 1.22) 0.87 (0.67, 1.14) 
        
*  All adjusted models control for contraceptive method, age, age at coital debut, and 
country  
  
 
 
 
 
 
 
 
CHAPTER 6: UNPROTECTED SEX IN HIV-INFECTED WOMEN IN UGANDA AND 
ZIMBABWE: SHORT- AND LONG-TERM COMPARISONS WITH PRE-INFECTION 
BEHAVIOR  
 
ABSTRACT 
 
Background: Recent HIV prevention initiatives focus on “positive prevention” – 
targeting and supporting HIV-infected individuals to modify their behavior and 
consequently reduce future transmission. However, despite the widespread 
promotion of male condoms to those living with HIV, no studies have systematically, 
prospectively measured condom use before and after HIV diagnosis. In a 
longitudinal cohort study that provided repeat HIV testing, counseling, and free 
condoms, we examined whether women decreased their unprotected sexual activity 
following notification of HIV-positive status. 
  
Methods: We analyzed data collected during a multi-site, prospective study among 
women in Zimbabwe and Uganda (Hormonal Contraception and HIV Acquisition 
(HC-HIV)). We used zero-inflated negative binomial models to examine changes in 
the number and proportion of unprotected sex acts in a typical month. We selected 
one visit two to six months before HIV diagnosis and paired it with a visit two to six 
months after diagnosis (short-term analysis) or 12-16 months after diagnosis (long-
term analysis). To track secular changes in condom use, we also included visits 
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spanning the same timeframes from a subset of randomly-selected uninfected 
women. 
 
Results: Short- and long-term findings were similar. We therefore present only long-
term results, conducted among 151 HIV-positive women and 650 uninfected 
comparison participants. After diagnosis, the number of HIV-infected women who 
reported any sex acts in a typical month decreased slightly (from 95% to 91%, 
p=0.14). The proportion of HIV-infected women reporting any unprotected acts 
declined more substantially (from 74% to 56%, p<0.01). In adjusted multivariable 
models, HIV-infected women were twice as likely to report no unprotected sex after 
diagnosis compared to pre-diagnosis behavior (odds ratio (OR): 1.99, 95% 
confidence interval (CI): 1.12 to 3.53); uninfected participants were somewhat less 
likely to report no unprotected sex (OR: 0.82, 95% CI: 0.64 to 1.04). Among those 
reporting any unprotected acts, HIV-infected women significantly reduced the 
number of unprotected sex acts in a typical month by 38% (95% CI: -16% to -55%) 
compared to pre-diagnosis behavior. However, HIV-positive women reported 
virtually no reduction in the proportion of unprotected acts in a typical month (7% 
reduction, 95% CI: -18% to +6%) after HIV diagnosis. Uninfected women reported 
little change in the number (2% increase, 95% CI: -8% to +12%) or proportion of 
unprotected acts (5% increase, 95% CI: +1% to +9%) over the same time period. 
 
Conclusions: Reductions in the absolute number of sex acts and the number of 
unprotected acts reported by HIV-infected women are encouraging, because for 
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those in serodiscordant couples, each protected act is a potential transmission 
averted. However, more than half of HIV-positive women still engaged in 
unprotected sex more than a year after HIV diagnosis, and despite the lower 
absolute number of unprotected acts, women did not improve the proportion of acts 
in which they used male condoms. In addition, the lack of change in condom use 
among uninfected women, despite repeated risk reduction counseling and provision 
of free condoms, suggests that alternative prevention interventions are needed for 
this population.  
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INTRODUCTION 
 
Recent HIV prevention initiatives focus on “positive prevention” – targeting and 
supporting HIV-infected individuals to modify their behavior and consequently 
reduce future transmission.
193-196
 Many randomized trials of positive prevention 
interventions measure changes in condom use to assess the efficacy of the 
intervention.
195
 When used consistently and correctly, latex male condoms are 
effective against sexual transmission of HIV and most STIs.
85-88
 
 
Despite the recent emphasis on positive prevention and the widespread promotion 
of male condoms to HIV-positive individuals, no studies have systematically and 
prospectively measured condom use before and after notification of HIV-positive 
status. Instead, some studies characterize risk behaviors (including condom use) of 
HIV-positive people after HIV diagnosis and compare them to behaviors reported at 
the time of notification of HIV-positive results;
195,197,198
 others make comparisons to 
a similar HIV-negative population to detect differences that might be due to 
awareness of HIV status. For example, HIV-positive Rwandan women were more 
likely to use condoms, and had a lower prevalence of gonococcal infection, than 
their HIV-negative peers.
127
 In the Democratic Republic of Congo and Kenya, HIV 
counseling and testing had little impact on fertility rates in HIV-positive women,
123,124
 
whereas HIV-positive Ugandan women had lower pregnancy rates than their HIV-
negative peers.
125,126
 In longitudinal studies of HIV-infected US women, enrolled 
after HIV diagnosis, substantial numbers of HIV-positive participants experienced 
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STIs during follow-up.
128,129
 Many HIV-positive US adolescents and adults continue 
to engage in high-risk behavior,
130
 with high proportions experiencing STI after HIV 
seroconversion.
131,132
 None of these studies captured condom use prior to 
individuals’ notification of their HIV-positive status, so direct, prospective 
measurements of changes in condom use were not possible.  
 
Is notification of HIV-positive status, together with risk reduction counseling, 
sufficient to induce and maintain increased condom use from pre-diagnosis 
behavior? We aimed to assess the effect of HIV diagnosis on women’s use of male 
condoms over shorter (two to six months after diagnosis) and longer (12 to 16 
months after diagnosis) time periods.  
 
METHODS   
 
This analysis draws data from the “Hormonal Contraception and Risk of HIV 
Acquisition” (HC-HIV) study, a prospective cohort study conducted in Uganda, 
Zimbabwe and Thailand, as well as an ancillary study involving the same 
participants called the “Effect of Hormonal Contraception on HIV Genital Shedding 
and Disease Progression among Women with Primary HIV Infection” (GS) study. 
HC-HIV had a primary objective to assess the effect of hormonal contraception on 
women’s risk of HIV acquisition, whereas GS enrolled and followed Ugandan and 
Zimbabwean women who became HIV infected during HC-HIV, with a primary 
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objective to examine the role of hormonal contraception use on HIV genital 
shedding and disease progression.  
 
Detailed methods and main findings for HC-HIV have been published elsewhere.
142
 
 
Study setting and population  
 
HC-HIV enrolled and followed women from 1999-2004. Eligible women were 18-35 
years of age; HIV-negative; sexually active and using either oral contraceptive pills 
(COCs), injectable depot medroxyprogesterone acetate (DMPA), or a non-hormonal 
or no contraceptive method.  
 
Starting in March 2001, all women in Zimbabwe and Uganda who became HIV-
infected during follow-up in HC-HIV were invited to enroll in GS. Because few 
incident HIV infections occurred in Thailand, the Thai site was not included in GS 
nor in the current analysis. 
 
All Zimbabwean and most Ugandan participants were recruited from family planning 
and maternal-child health clinics. Owing to low initial HIV incidence rates among 
Ugandan women, recruitment there was expanded to include referrals from “higher-
risk” populations, such as sexually transmitted disease clinics, sex workers and 
military wives.  
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Study procedures 
 
HC-HIV study 
At enrollment and each follow-up visit, women received structured, face-to-face 
interviews about their reproductive, contraceptive and sexual behavior, including use 
of male condoms. They also received physical exams with biological specimen 
collection for HIV and STI testing. Standard counseling on use of male condoms 
accompanied all HIV pre- and post-test counseling sessions. Follow-up visits took 
place approximately every three months for up to two years or until HIV 
seroconversion.  
 
GS study 
Women who became HIV-infected during HC-HIV were told about GS; interested 
women returned to the clinic for GS enrollment. GS participants who joined soon 
after HIV diagnosis had multiple early follow-up visits (at 2, 4 and 8 weeks after GS 
study entry); follow-up visits then took place, as in HC-HIV, approximately every 
three months. At each GS visit the same face-to-face HC-HIV questionnaires were 
administered to collect reproductive and sexual behavior information; women also 
underwent a physical examination with specimen collection. At every GS visit, 
participants received counseling and condom use instructions as well as a supply of 
free condoms. 
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Statistical analyses 
 
Statistical analyses were performed using SAS (Version 9.1.3, SAS Institute, Cary, 
NC) and Stata (Version 9.2, Statacorp, College Station, TX). 
 
Exposure measure: notification of HIV-positive status 
Participants received HIV tests at every HC-HIV follow-up visit using a combination 
of two enzyme-linked immunosorbent assays or rapid tests. Positive results were 
confirmed by Western Blot or HIV polymerase chain reaction tests. Following a 
positive result, the participant was called back for a redraw visit (10-21 days after 
the initial test) to rule out labeling errors. At the redraw visit, counselors informed the 
woman that her HIV test appeared positive, but that further confirmatory tests were 
needed. A result was typically given to the participant within 1-2 weeks of the redraw 
visit. For this analysis, we used the date of the redraw visit, when women were first 
told they were likely infected with HIV, as the date of HIV diagnosis. 
   
Outcome measure: Number of unprotected sex acts in a typical month  
At each follow-up visit, during both HC-HIV and GS, participants were asked: “In the 
last three months, in a typical month, how many times did you have sex?” and “In 
the last three months, in a typical month, how many times did your partner use a 
male condom during sex with you?” Women answered these questions about all 
partners, separately for primary and other partners. The number of unprotected sex 
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acts in a typical month was calculated as the total number of sex acts with all 
partners minus the total number of sex acts where male condoms were used.  
 
Analytic procedures 
 
We examined condom use in two analyses, merging data collected during HC-HIV 
with data collected during GS (Figure 3.2).   
 
Short-term comparison  
Our first analysis examined short-term changes in participants’ self-reported condom 
use. For women who experienced HIV infection during HC-HIV, we selected one 
HC-HIV visit two to six months prior to notification of HIV-positive status (the 
“before” visit) and one GS visit two to six months after HIV diagnosis (“after” visit). 
To capture any secular changes in condom use that may have taken place over the 
follow-up period, and to consider whether condom use was associated with HIV 
acquisition, we also included visits from women who did not become HIV-infected 
during HC-HIV. From all HC-HIV visits contributed by uninfected women, using 
SAS’s random number generator, we randomly selected one “anchor” visit, then 
chose corresponding visits two to six months before and two to six months after the 
anchor visit. From all uninfected women with visits within the specified timeframe, 
we randomly selected a sample in an approximate 4:1 ratio with HIV-infected 
women.  
 
  129 
Long-term comparison 
Second, we examined changes in self-reported condom use over a longer time 
period.  For women who became HIV-infected, we again selected one HC-HIV visit 
two to six months prior to notification of HIV-positive status, but we paired it with one 
GS visit 12-16 months after HIV diagnosis. For women remaining uninfected, we 
chose corresponding visits two to six months before the randomly-selected anchor 
visit and 12-16 months after the anchor visit. We again randomly selected a sample 
of uninfected women in an approximate 4:1 ratio with HIV-infected participants.  
 
Although the same number of uninfected women were selected for short- and long-
term analyses (n=650 for each), because of the random selection process and the 
timeframe requirements, uninfected participants included in the long-term analysis 
were not necessarily the same uninfected women as in the short-term analysis. 
 
Visit selection 
The goal of visit selection for each analysis was to have a pair of observations for 
each participant, with one “before” and one “after” measure. To be included in these 
analyses, HIV-infected women had to have GS visits within the specified timeframes 
(within six months of the redraw visit for the short-term analysis and at least 12 
months after the redraw visit for the long-term analysis). Some HIV-infected women 
joined GS in sufficient time to be included in the short-term analysis but did not 
continue follow-up in GS long enough to be included in the long-term analysis. 
Similarly, uninfected women had to participate in HC-HIV long enough for 
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comparison measures to be captured (at least two months after their randomly-
assigned anchor visit for the short-term analysis and at least 12 months after their 
anchor visit for the long-term analysis). When participants (HIV-infected or 
uninfected) contributed more than one visit within the specified timeframe, we chose 
the visit with non-missing data on condom use that was closest to the beginning of 
the window (e.g. closer to two months than six months, or closer to 12 months than 
16 months).  
 
Comparisons of coital frequency and unprotected sex  
Using McNemar’s test,
199
 we examined whether the number of women reporting any 
sex acts in a typical month, or the number reporting any unprotected acts, changed 
a short and longer period after HIV diagnosis (for HIV-infected women) or anchor 
visit (for uninfected women). Using Student’s t-test, we compared the mean number 
and proportion of unprotected acts among women who ultimately became HIV-
infected and participants who remained HIV negative.
200
 
 
Multivariable models 
Because our outcome (number of unprotected sex acts) was a count, we considered 
and compared the fit of regression models using the Poisson, negative binomial, 
zero-inflated Poisson and zero-inflated negative binomial (ZINB) distributions.
177-179
 
ZINB provided the best fit, and we subsequently used ZINB models to examine the 
change, with 95% confidence intervals (CIs), in the number of unprotected sex acts 
in a typical month.  
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Many condom use studies explore the proportion of sex acts where male condoms 
were used (or not used). However, because risk of sexual HIV transmission is more 
directly correlated with the number of unprotected sexual exposures, we were also 
interested in the absolute number of sex acts where condoms were not used. We 
ran each ZINB multivariable model without and then with an offset variable capturing 
the total number of sex acts in a typical month. Without the offset, the model 
predicted the number of unprotected acts in a typical month; with the offset, the 
model predicted the proportion of unprotected acts in a typical month. 
 
ZINB models follow a two-step process. The first is a logistic model that predicts a 
binary outcome: zero vs. more than zero in the value of the count. The second 
process is a negative binomial model including those observations with a count 
value more than zero; it predicts the value of the non-zero count. Parameter 
estimates are produced for both model steps.  
 
Effect estimates from the logistic procedure can be interpreted as an odds ratio 
(OR) comparing the odds of having no unprotected acts in a typical month after HIV 
diagnosis (for HIV-positive women) or anchor visit (for uninfected women), with the 
odds of having no unprotected acts in a typical month beforehand. A measure 
greater than 1.0 indicates that the odds of having no unprotected acts in a typical 
month after HIV diagnosis or anchor visit has increased compared to the odds of 
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having no unprotected acts in a typical month beforehand (in other words, that the 
odds of having any unprotected acts has decreased).  
Interpretation of effect estimates from the negative binomial portion of the model 
changes depending on whether an offset variable is included (inclusion of the offset 
does not affect interpretation of the logistic portion of the model). Without an offset, 
effect estimates from the negative binomial portion of the model represent the 
relative change in the number of unprotected acts in a typical month after HIV 
diagnosis or anchor visit, compared to the number of unprotected acts in a typical 
month beforehand. A measure less than 1.0 indicates that the number of 
unprotected sex acts in a typical month has declined.  
 
When including an offset variable for the total number of sex acts in a typical month, 
the measure of effect from the negative binomial portion of the model can be 
interpreted as a relative change in the proportion of acts in a typical month where 
male condoms were not used. Interpretation is otherwise similar: a measure less 
than 1.0 indicates that the proportion of all acts where male condoms were not used 
has declined. 
 
To generate separate effect estimates for HIV-infected and uninfected participants, 
we used three independent variables in both the logistic and negative binomial 
portions of the ZINB model: HIV, coded 0 for women who remained HIV-negative 
throughout HC-HIV and 1 for women who became HIV-infected; timepoint, coded 0 
for visits prior to HIV diagnosis (for women experiencing HIV infection) or anchor 
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visit (for women remaining HIV-negative) and 1 for visits after; and a product 
interaction term between timepoint and HIV.  
 
We used robust variance estimation to account for non-independence resulting from 
repeated measures on individual participants.
160
 
 
We examined participants’ demographic characteristics, reproductive factors and 
sexual behavior for their confounding influence on the association between HIV 
diagnosis and condom use. We included in each starting multivariable model all 
factors that were associated with HIV-positive status or condom use. We did not 
include in models variables which could be affected by notification of HIV-positive 
status.
156
 
 
To construct final models, we used a manual, backward elimination, change-in-
estimate strategy.
164
 One at a time, we removed covariates from the starting model; 
if removal changed the condom use association by less than 10%, a given covariate 
was not retained. We designated models as “final” when the remaining covariates 
confounded the main association or were retained for a priori considerations (age).  
 
Any covariate that confounded the estimate for HIV-infected participants or for 
uninfected women, in short- or long-term analyses, in the logistic or negative 
binomial portions of the model, in a model with or without the offset variable, was 
included in the final adjustment set for all other analyses.  
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Ethical approval 
All women enrolled in HC-HIV and GS gave written informed consent prior to 
participating, and local ethics committees at collaborating institutions gave approval 
for the studies.  
 
RESULTS 
 
Short-term changes in self-reported condom use 
 
Selection of HIV-infected and uninfected participants 
Of 213 Ugandan and Zimbabwean women who became HIV-infected during HC-
HIV, 189 (89%) eventually participated in GS. A smaller proportion, 74% (n=158) 
had a GS visit within the specified window of two to six months after HIV diagnosis 
and are included in the short-term comparison. For these 158 participants, the 
median time between the “before” visit and the redraw visit was 3.3 months 
(interquartile range (IQR): 2.8-3.9 months), and the median time between the redraw 
visit and the “after” visit was 2.7 months (IQR: 2.3-3.7 months).  
 
From 4,226 HC-HIV participants who remained HIV-uninfected, 650 women were 
randomly selected for the short-term analysis. For these uninfected women, the 
median time between the “before” visit and the anchor visit was 2.7 months (IQR: 
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2.6-2.8 months), and the median time between the anchor visit and the “after” visit 
was also 2.7 months (IQR: 2.6-2.9 months). 
 
Because participant characteristics (Table 6.1), changes in coital frequency and 
frequency of unprotected sex (Table 6.2), and results of multivariable models (Table 
6.3 and Table 6.4) for short-term comparisons were similar to the long-term 
analyses, due to space considerations we describe only the long-term findings in 
detail (see below).  
 
Long-term changes in self-reported condom use 
 
Selection of HIV-infected and uninfected participants 
Of 189 HIV-infected women who joined GS, 151 participants (80%) had a GS visit 
12-16 months after HIV diagnosis. For these 151 women, the median time between 
the “before” visit and the redraw visit was 3.2 months (IQR: 2.7-3.7 months), and the 
median time between the redraw visit and the “after” visit was 13.8 months (IQR: 
13.1-14.3 months). Uninfected women (n=650) for the long-term comparison were 
selected from the 4,226 HC-HIV participants who remained HIV-uninfected; these 
participants were selected independent of inclusion in the short-term analysis. The 
median time between the “before” visit and the anchor visit for uninfected women in 
the long-term comparison was 2.7 months (IQR: 2.6-2.9 months), and the median 
time between the anchor visit and “after” visit was 13.5 months (IQR: 13.1-14.0 
months).  
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Most HIV-infected women in the long-term analysis (91%, n=137) were also 
included in the short-term analysis. Approximately one-third of uninfected 
participants (35%, n=225) were common to both the short- and long-term analyses.  
 
Participant characteristics (Table 6.1) 
At the visit two to six months before HIV diagnosis, women who ultimately became 
HIV-infected were less likely than women remaining HIV-negative to be from 
Uganda (36% vs. 56%), although the proportion recruited from high-risk settings in 
Uganda was similar (11% vs. 10%) (Table 6.1). Half of all participants were 
employed, and most (76%-83%) lived with their primary partner. Mean age (25.0 vs. 
25.5 years), mean age at coital debut (17.5 years in both groups) and mean years of 
education (9.1 for both groups) was similar between participants who ultimately 
became HIV-infected and those remaining uninfected.  Alcohol or drug use during 
sex in the last three months was rare (3%-4%), and commercial sex was also 
uncommon (1% in both groups). Women who became HIV-infected were more likely 
than women remaining uninfected to report multiple partnerships in the last three 
months (7% vs. 3%) and to have a higher mean number of nights in the last month 
that the partner spent away from home (8.0 vs. 6.7 nights).  
 
Changes in coital frequency and frequency of unprotected sex 
We first examined changes in the number of HIV-infected and uninfected 
participants who reported any sex acts in a typical month (Table 6.2). The number of 
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women engaging in sex declined somewhat over the long term. Two to six months 
before HIV diagnosis, 144 participants (95%) who ultimately became HIV-infected 
reported at least one sex act in a typical month; 12-16 months after notification of 
HIV-positive status, 137 women (91%) reported at least one sex act in a typical 
month (p=0.14). Of uninfected women, 642 (99%) reported at least one sex act two 
to six months before the anchor visit, compared to 623 women (96%) who reported 
at least one sex act 12-16 months after the anchor visit (p<0.01) (Table 6.2). 
 
We next examined whether the number of women reporting any unprotected sex 
acts changed over the long-term. Among HIV-infected women reporting at least one 
sex act, the number who had at least one unprotected act in a typical month 
declined significantly after diagnosis: two to six months before notification of HIV-
positive status, 107 participants (74%) who ultimately became HIV-infected reported 
at least one unprotected act in a typical month; two to six months after notification of 
HIV-positive status, 77 women (56%) reported at least one unprotected act in a 
typical month (p<0.01). Uninfected women showed almost no change: among those 
with at least one sex act, 486 (75%) two to six months before the anchor visit, 
compared to 489 women (79%) 12-16 months after the anchor visit (p=0.87), 
reported at least one unprotected act in a typical month (Table 6.2). 
 
Among women reporting at least one unprotected act in a typical month, we also 
examined changes to the mean total number of sex acts, the mean number of 
unprotected acts, and the proportion of sex acts where condoms were not used in a 
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typical month (Table 6.2). Among this subgroup, HIV-infected women showed 
significant declines in their overall mean coital frequency, but less substantial 
changes in the mean number of unprotected acts and virtually no change in the 
proportion of sex acts where condoms were used. Two to six months prior to 
notification of HIV-positive status, among those with at least one unprotected act, 
women who ultimately became HIV-infected reported a mean of 19.9 total sex acts 
and 11.2 unprotected acts in a typical month; they reported that condoms were not 
used in 79% of sex acts. After diagnosis, HIV-infected participants with at least one 
unprotected act reported means of 9.5 total sex acts and 7.0 unprotected acts in a 
typical month; the proportion of sex acts where condoms were not used was again 
79%. In contrast, uninfected women with at least one unprotected act reported a 
mean of 14.9 total sex acts and 11.8 unprotected acts in a typical month before the 
anchor visit, very similar to the 14.2 mean total sex acts and 11.0 mean unprotected 
acts reported after the anchor visit (Table 6.2). The proportion of sex acts where 
condoms were not used among uninfected women was 84% prior to the anchor visit 
and 87% afterwards. 
 
Of note, among women reporting at least one unprotected act in a typical month at 
the “before” visit, women who ultimately became HIV-infected did not differ 
significantly from women who remained uninfected in their mean number of 
unprotected acts (11.2 acts vs. 11.8 acts, p=0.62) or the mean proportion of 
unprotected acts (79% vs. 84% unprotected, p=0.09). 
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Multivariable long-term models 
Because women who reported zero sex acts in a typical month were not at risk of 
the outcome (number of unprotected acts), these observations were excluded from 
multivariable models. 
 
Long-term changes in the number of unprotected sex acts (Table 6.3) 
In unadjusted analyses, women who experienced HIV infection were approximately 
twice as likely to report no unprotected sex in a typical month after notification of 
HIV-positive status compared to their pre-diagnosis visit (OR: 2.19, 95% CI: 1.28 to 
3.74). Uninfected women had somewhat lower odds of reporting no unprotected 
acts in a typical month (in other words, higher odds of having any unprotected acts) 
12-16 months after their anchor visit (OR: 0.84, 95% CI: 0.67 to 1.05) compared to 
two to six months before the anchor visit (Table 6.3). 
 
Among those who reported any unprotected acts, 12-16 months after notification of 
HIV-positive status, HIV-infected women had a 40% reduction (95% CI: -19% to -
56%) in the number of unprotected sex acts in a typical month compared to the pre-
diagnosis period. Uninfected women did not substantially change their number of 
unprotected acts in a typical month (1% increase, 95% CI: -8% to +12%) following 
their anchor visit.  
 
We refit our models after adjusting for variables that confounded associations with 
condom use (age, country, recruitment population, prior STI during study, and 
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partner symptomatic of STI in past three months). Adjusted measures of effect were 
similar to unadjusted estimates (Table 6.3): HIV-infected women were twice as likely 
to report no unprotected sex after HIV diagnosis (OR: 1.99, 95% CI: 1.12 to 3.53), 
and uninfected women had somewhat lower odds of no unprotected acts after their 
anchor visit (OR: 0.82, 95% CI: 0.64 to 1.04). Among those who reported any 
unprotected acts, 12-16 months after diagnosis, HIV-positive women had an 
adjusted decline in sex acts of 38% (95% CI: -16% to -55%). Uninfected women did 
not substantially change their number of unprotected acts in a typical month (2% 
adjusted increase, 95% CI: -8% to +12%) following their anchor visit. 
 
Long-term changes in the proportion of unprotected sex acts (Table 6.4) 
Inclusion of an offset variable for the total number of sex acts did not have a large 
influence on the logistic portion of the unadjusted model. HIV-infected women still 
had increased odds of reporting no unprotected sex acts 12-16 months after 
diagnosis, and uninfected women continued to have decreased odds of reporting no 
unprotected sex acts after the anchor visit (Table 6.4). Effect estimates did not 
meaningfully change for either group following multivariable adjustment (Table 6.4). 
 
Accounting for the total number of sex acts, however, had a strong influence on the 
negative binomial portion of the long-term model compared to the model without the 
offset. After diagnosis, HIV-infected women had virtually no reduction in the 
proportion of sex acts where male condoms were not used (4% reduction 
(unadjusted), 95% CI: -15% to +10%). Uninfected women similarly had no 
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meaningful change (4% increase (unadjusted), 95% CI: -0% to +8%). Adjustment for 
confounding variables did not substantially alter the proportion of total sex acts 
where male condoms were not used for HIV-infected or uninfected women (Table 
6.4). 
 
Restricting the analysis datasets to include only participants contributing complete 
pairs of “before” and “after” visits did not meaningfully change the short- or long-term 
effect estimates (data not shown). 
 
DISCUSSION 
 
In this prospective analysis, women who were made aware of their HIV infection 
modified their behavior in several ways that protected their partners from exposure. 
Although most did not abstain altogether from coitus, HIV-infected participants were 
less likely to report any unprotected sex acts, and among those with at least one 
unprotected act, they reduced the absolute number of unprotected acts in a typical 
month. Although these results are encouraging, the proportion of HIV-positive 
women reporting some unprotected sex remained fairly high (56%) more than a year 
after diagnosis. In addition, although HIV-infected women modified the number of 
unprotected acts, the proportion of unprotected acts was nearly unchanged from 
pre-infection behavior. These results contrast with women who remained HIV-
negative, who exhibited few substantive changes over equivalent follow-up periods.  
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Reductions in risky behavior were evident both though a decline in the number of 
women reporting any unprotected sex and, among those who continued to have 
unprotected sex, through the decreased number of unprotected acts that they 
engaged in. However, those HIV-infected participants that continued to have some 
unprotected sex did not increase the proportion of acts in which condoms were 
used, suggesting that condom promotion messages delivered though HIV post-test 
counseling were not sufficient to change condom use behaviors among these 
participants and their partners. 
  
From a public health perspective, a reduction in the number of unprotected acts is 
more important than a change in the proportion of acts where male condoms were 
used. Sexual transmission of HIV occurs through an act of unprotected sex. 
Whether that act is a large or small proportion of all sex acts is less relevant. 
Because HIV-infected women in this cohort significantly reduced their number of 
unprotected acts, susceptible partners of HIV-infected women likely faced reduced 
HIV risk. For example, a woman who has 20 total sex acts, with 10 acts 
unprotected, before notification of HIV-positive status and 10 total sex acts, with 5 
acts unprotected, afterwards has used condoms in an equivalent proportion of acts 
(50% in each case). After diagnosis, however, her partner is exposed to HIV fewer 
times, and is therefore at lower risk of acquisition.  
 
The lack of change in condom use among uninfected women, who also received 
risk reduction counseling and free male condoms throughout the study, suggests 
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that counseling and supplies alone are not sufficient to reduce unprotected sex. 
Importantly, most women in this cohort were in monogamous relationships, and they 
cohabitated with their partner; condom use in primary partnerships among both 
general population and higher-risk developing country cohorts has consistently been 
found to be low.
201-204
 At HC-HIV baseline, 4% of COC users, 7% of DMPA users, 
and 63% of users of non-hormonal methods reported always using condoms, 
whereas 76% of COC users, 77% of DMPA users, and 17% of users of non-
hormonal methods reported never using condoms.
205
 Given that the probability of 
HIV transmission from infected men to susceptible women may be higher than from 
infected women to susceptible men,
206,207
 an improvement in condom use among 
uninfected women may be more important from a public health perspective than 
improvements by HIV-positive women.  
 
The decline in number of unprotected acts among HIV-infected women may be due 
to factors other than intentional risk-reduction behavior change. At the visit two to six 
months prior to HIV diagnosis, a woman may have reported riskier behavior than is 
typical for her – for most participants, the “before” visit occurred around the time of 
HIV acquisition – and so reductions in risk following notification of HIV infection may 
simply be a return to more typical behavior. Women who disclosed HIV status to 
their partners may have experienced relationship dissolution and consequent 
reductions in overall coital frequency and numbers of unprotected acts (we 
unfortunately did not collect data on disclosure to partners). Decreased sexual 
activity could also be due to depression following diagnosis, or (particularly for long-
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term analyses) to HIV-related illness in a woman’s partner, resulting in decreased 
sexual drive.   
 
Our analysis addresses a number of gaps in the previous literature on this topic. 
First, no published study has compared women’s reported condom use from the 
period prior to HIV diagnosis with condom use both a short and longer time after 
notification of infection status. Because we systematically captured women’s 
condom use prior to diagnosis, our measure was not biased by women’s knowledge 
of their status or the presence of symptoms that may have prompted them to modify 
condom use. Second, much of the research examining risk behavior after HIV 
acquisition has been conducted among specialized, high-risk populations (in the US, 
in adolescents or gay men; in international settings, in sex workers or truckers) and 
is not readily generalizable to the large proportion of general population women in 
our cohort. Finally, earlier studies that tracked changes in condom use after 
infection typically did so for a limited period of time, often for three months or less. 
Our long-term analysis demonstrates that behavior changes may be sustained over 
many months, and that a regression to baseline behavior may be avoidable.  
 
In preliminary analyses, we examined changes to condom use associations when 
multivariable models were adjusted for contraceptive method, cohabitation with the 
primary partner, and recent pregnancy. Because each of these variables may be 
associated with condom use, we initially evaluated them as possible confounders. 
However, they may also be affected by notification of HIV positive status,
156
 and lie 
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on the causal pathway between HIV diagnosis and behavior change. We ultimately 
decided to exclude all three variables from final models for this reason. Of note, the 
magnitude of modeling estimates did not change meaningfully when these variables 
were included (data not shown). We also initially included women’s time since 
enrollment in HC-HIV as an adjustment variable in the modeling analyses, to 
account for participants’ varying exposure to condom counseling messages. Due to 
substantial collinearity with several other covariates, the precision of our effect 
estimates declined considerably when this variable was included. Removing it from 
the models had very little influence on validity (since the magnitude of the measures 
of effect changed very little), and we ultimately chose to exclude it because of 
precision concerns.
208
   
 
Our analyses also suffer from a number of limitations. Most importantly, the number 
of unprotected sex acts was self-reported by women and may have been influenced 
by recall and social desirability biases. For example, notification of HIV-positive 
status may affect women’s reports of condom use, rather than affecting actual 
condom use. Because such misreporting could be differential by HIV status, the 
resulting bias is unpredictable and could lead to inflated or attenuated effect 
estimates. Second, we do not know which participants had HIV-infected partners. If 
a woman knew that her sex partner was already HIV-positive, she would likely lack 
incentive to reduce unprotected sex upon learning of her own positive status. Our 
estimates therefore reflect a combination of women who did and did not need to 
“protect” their sex partners from subsequent infection.  
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Third, we made two simplifying assumptions that could have influenced our findings: 
we computed the number of unprotected acts as the total number of acts minus acts 
where male condoms were used, without taking account of women’s use of female 
condoms. Female condoms are not widely available in Zimbabwe and Uganda and 
are expensive where they can be purchased, so we do not expect that this 
assumption will lead to substantial bias. Of women included in short-term analyses, 
for example, at HC-HIV baseline, only 9 women (5%) who ultimately seroconverted 
and 10 women (2%) remaining uninfected reported ever using a female condom. In 
addition, we collapsed sexual behavior with primary and non-primary sexual 
partners. Most women did not have multiple partners – at the “before” visit, 6-7% of 
women ultimately becoming HIV-infected and 1-3% of participants remaining 
uninfected reported more than one sexual partner in the last three months – and we 
expect any bias to be minimal. Finally, we acknowledge that women may make 
different decisions upon discovering they are HIV-infected, and a change in condom 
use is only one; changes in multiple partnerships, concurrent partnerships, 
commercial sex work or other risky behavior among HIV-infected women are also 
possible. Although we examined these behaviors in preliminary analyses (data not 
shown), because they were not commonly reported by participants at any visit 
regardless of HIV status, we did not have adequate power to detect changes over 
the follow-up period.   
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We undertook these analyses to explore a fundamental assumption in HIV 
prevention interventions – that proper information and adequate supplies can induce 
HIV-infected individuals to reduce their risk behavior and prevent subsequent 
transmission to vulnerable partners. Due to both reductions in the number of women 
engaging in unprotected sex and through declines in overall coital frequency, HIV-
infected Ugandan and Zimbabwean women in this cohort reduced the risk of HIV 
transmission to susceptible partners and sustained these behavior changes more 
than a year after HIV diagnosis.  
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CHAPTER 7: DISCUSSION 
 
As of January 6 [1986], the C.D.C. reported a cumulative total of 
16,138 cases of AIDS, resulting in 8,220 deaths so far. ... “I fear it will 
get worse before it gets better,” said Dr. Ward Cates, head of the 
sexually transmitted disease division at the Federal centers. ...” 
-New York Times, Philip M. Boffey, 14 January 1986  
 
More than 25 years have passed since the perplexing immunodeficiency syndrome, 
later characterized as AIDS, was first noted among five previously healthy gay men 
in Los Angeles.
209
 As the outbreak grew from local clusters within marginalized 
communities to a worldwide pandemic affecting people of all ages and 
demographics – by December 2006, 40 million people worldwide were estimated to 
be infected with HIV
2
 – efforts to prevent transmission of the virus have also seen 
exponential growth in scope and intensity. The results of most HIV-prevention 
programs, however, have been disappointing. Two interventions have been notable 
exceptions to this dismal history: by 1983, researchers had noted that consistent 
use of male condoms appeared to reduce the probability of transmission of disease 
from infected individuals to their susceptible sex partners.
210-212
 Much more recently, 
in November 2005 and February 2007, large-scale randomized trials determined 
that men who were circumcised had 40-65% reduced risk of HIV acquisition 
compared to their uncircumcised peers.
19-21
 These “bookend” interventions – one at 
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the very start of the epidemic, and one just definitively confirmed in recent weeks – 
are the focus of these dissertation analyses. 
 
Male circumcision and women’s risk of HIV and STI 
 
Summary of findings 
 
Our analyses focused on the impact of these two interventions specifically among 
women. Few previous studies had investigated the influence of MC on women’s HIV 
risk; the three published prospective reports all indicated that women with 
circumcised partners had lower HIV risk than those with uncircumcised partners.
64-67
 
For most women in our cohort, however, MC was not associated with decreased risk 
of HIV. For a small subgroup of participants recruited from high-risk settings, there 
was a non-significant suggestion of reduced HIV risk among women with 
circumcised partners compared to those with uncircumcised partners. Our Ct 
results, which suggest little effect of MC on women’s Ct risk, agrees with one of two 
previous analyses of MC and chlamydial risk among women.
67
 The second study on 
MC and Ct reported that women whose partners were circumcised were strongly 
protected against Ct acquisition.
73
 The direction of our observed association is the 
opposite of this second study, as women in our cohort who reported uncircumcised 
partners appeared to have somewhat lower Ct risk, particularly when the analysis 
was restricted to women with only one sexual partner. The one previous study that 
evaluated MC and women’s risk of GC found no association,
67
 and the same study 
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reported that MC was protective against women’s infection with prevalent Tv.
67
 We 
found no association between MC and these infections in our cohort. 
 
Interpretation 
Despite the great promise of MC to reduce HIV risk among men, we did not find 
substantial protection for most women in our cohort. We note that because we had 
HIV/STI incidence measures on women only and not their sexual partners, we were 
unable to separately assess the two mechanisms through which women’s disease-
acquisition risk could be altered: if circumcision allowed a man to avoid initial 
infection, and thereby reduced or eliminated the risk of infection in his sex partners, 
or, if circumcision reduced the transmissibility of HIV from infected men to 
susceptible women. Given that the recent MC-HIV trials are being interpreted as 
definitive confirmation that circumcised men have lower HIV risk, it is somewhat 
surprising that we did not see more of an impact of MC among women in our study 
through the first mechanism, even if the second proposed mechanism had no effect.  
 
MC is only one factor that may raise or lower men’s risk of HIV acquisition. Although 
we attempted to assess and control for men’s behavior (as reported by their female 
partners), risky sexual practices by men (such as multiple and concurrent 
partnerships, prevalent STI, and other factors) may have “overwhelmed” the 
protective effect of MC for the male partners of women in our study. (We did not 
observe confounding by those partner-level risk behaviors that were measured). If 
circumcised partners of women in our study were HIV-infected in similar proportions 
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as uncircumcised partners, and circumcision is not associated with a direct 
reduction in risk of HIV transmission to susceptible women, it follows that HIV risk to 
women in our cohort would not differ by circumcision status of women’s sex 
partners.  In addition, the protection conferred to men by MC is not complete. If the 
circumcised primary partner of a woman in our cohort was previously partnered with 
an HIV-infected woman, over time the cumulative probability of HIV transmission to 
that man due to repeated HIV exposure may well have been greater than the 
protection provided by his circumcised status.   
 
Public health significance 
Male circumcision may “provide a degree of protection … equivalent to what a 
vaccine of high efficacy [could] achieve.”
 19
 Recent trials showing significant declines 
in HIV risk for circumcised men compared to uncircumcised men have been met 
with great enthusiasm and optimism, and intervention programs are being planned 
worldwide. Modeling simulations, accounting for changes in HIV prevalence to men 
directly and to their female sex partners indirectly, found that MC could avert two 
million new HIV infections and 300,000 deaths in sub-Saharan Africa in the first ten 
years of an MC intervention with full coverage. In the ten years after that, it could 
avert a further 3.7 million new HIV infections and 2.7 million deaths.
15
  
 
Future research directions 
Although MC interventions are currently being planned worldwide, significant 
questions remain about the efficacy of this intervention for non-HIV STIs and for 
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women. None of these outstanding questions will (or should) delay the planned 
interventions, but monitoring and follow-up analyses should be conducted alongside 
the prevention programs to answer unknown questions about efficacy of MC for 
other outcomes and populations. For example, previous observational research 
suggests that MC lowers men’s risk of acquisition of syphilis and chancroid.
29
 We 
could not assess the associations between MC and these infections in women 
because we did not have data on incident chancroid or syphilis among female 
participants in our cohort. Because transmission mechanisms for ulcerative STIs 
differ from those for HIV or bacterial STIs, a quantification of the association 
between MC and women’s risk of chancroid and syphilis would be helpful.  
 
In addition, as noted above, we were unable to determine whether associations 
between MC and women’s HIV risk were due to men’s reduced risk of initial HIV 
acquisition and subsequent reductions in women’s exposure to HIV-infected men, or 
whether MC directly altered the probability of HIV transmission from infected men to 
susceptible women. Ultimately a quantification of these distinct components is 
needed. A prospective, HIV-serodiscordant couples’ study (HIV-positive men and 
HIV-negative women) is a superior design to parse these effects, and such a study 
is currently underway in Rakai, Uganda. Better control of confounding factors related 
to men’s sexual behavior is a second advantage of a couples’ study, since male 
partners are study participants in their own right and provide information about their 
own behavior, rather than women guessing about their partners’ risk factors. We 
note that in the HC-HIV study, however, women’s HIV risk was correlated with 
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reported risk behavior of the primary partners,
142
 indicating that these women had 
accurate perceptions about partner behavior.  
 
HIV diagnosis and changes in condom use  
Summary of findings 
Our second analysis aimed to explore a fundamental assumption of post-diagnosis 
counseling efforts directed at HIV-positive individuals. With comprehensive 
counseling and unlimited condom supplies, do HIV-positive women actually change 
their condom use after diagnosis? Women who became HIV-infected did modify 
their behavior in several ways that protected their partners from exposure to HIV. 
Although most did not abstain altogether from coitus, HIV-infected participants had 
lower sexual frequency, were less likely to report any unprotected sex acts, and had 
a reduced mean number of unprotected acts in a typical month both a short and 
longer period after notification of HIV-positive status. Although these results are 
encouraging, the proportion of HIV-positive women reporting at least one 
unprotected act remained fairly high (56%) more than a year after diagnosis. In 
addition, although HIV-infected women modified the number of unprotected acts, 
after adjustment for confounding factors, the proportion of unprotected acts was 
nearly unchanged from pre-infection behavior. These results contrast with women 
who remained HIV-negative, who exhibited few substantive changes over equivalent 
follow-up periods.  
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Reductions in risky behavior were evident both though a decline in the number of 
women reporting any unprotected sex and, among those who continued to have 
unprotected sex, through the decreased number of unprotected acts that they 
engaged in. However, those HIV-infected participants that continued to have some 
unprotected sex did not increase the proportion of acts in which condoms were 
used, suggesting that condom promotion messages delivered though HIV post-test 
counseling were not sufficient to change condom use behaviors among these 
participants and their partners. 
 
Interpretation 
The results of our analysis of condom use behavior among HIV-positive women 
differ somewhat from other studies on this topic. Although no previous published 
paper has prospectively, systematically compared condom use before and after HIV 
acquisition, studies attempting to answer a similar research question generally found 
that changes in risky behavior were short-lived.
102,110,114
  
 
We note that the decline in the number of unprotected acts among HIV-infected 
women could be due to factors other than an intentional choice to reduce risky 
behavior. For example, at the visit two to six months prior to HIV diagnosis, a 
woman may have reported riskier behavior than is typical for her – for most 
participants, the “before” comparison visit occurred around the time of HIV 
acquisition – and so reductions in risk following notification of HIV infection may 
simply be a return to her more typical behavior. Alternatively, women’s decreased 
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sexual activity could be a result of depression after learning their serostatus. Of 
course, coital frequency and condom use also depend on the behavior of women’s 
primary partner. Women who disclosed HIV status to their partners may have 
experienced relationship dissolution and consequent reductions in overall coital 
frequency and numbers of unprotected acts. We unfortunately did not collect data 
on serostatus disclosure to partners. However, 91 HIV-positive women (58% of 
included HIV-infected women) in the short-term analysis and 92 women (61%) in the 
long-term analysis reported either no primary partner or a different primary partner 
at some point over GS follow-up (not necessarily at the “after” comparison visit). 
Whether these partnership changes were the direct result of HIV serostatus 
disclosure is unknown. Finally, even for women whose relationships remained intact, 
participants (or more likely, their partners) may have become symptomatic and 
experienced decreased sexual drive.  
 
Public health significance 
Women’s use of male condoms with partners is an inherently difficult topic. Since, 
as a physical reality, women do not “wear” the condom, they often lack control over 
decisions related to its use. Despite this (very large) limitation in the promotion of 
male condoms for HIV prevention, aside from abstinence, condoms are the most 
widely-promoted method to reduce the probability of disease transmission.  
 
Our analysis explored changes in condom use in a very particular setting – HIV 
diagnosis accompanied by comprehensive counseling and unlimited condom 
  162 
supplies. The substantial reductions in risky behavior observed among these 
participants, evident both though a decline in the number of women reporting any 
unprotected sex and, among those who continued to have unprotected sex, through 
the decreased number of unprotected acts that they engaged in, may therefore not 
be generalizable to populations where condoms and counseling are not so readily 
available to HIV-infected individuals.  
 
The lack of change in condom use among uninfected women, who also received 
risk reduction counseling and free male condoms throughout the study, suggests 
that counseling and supplies alone are not sufficient to reduce unprotected sex. 
Importantly, most women in this cohort were in monogamous relationships, and they 
cohabitated with their partner; condom use in primary partnerships among both 
general population and higher-risk developing country cohorts has consistently been 
found to be low.
201-204
 Given that the probability of HIV transmission from infected 
men to susceptible women may be higher than from infected women to susceptible 
men,
206,207
 an improvement in condom use among uninfected women may be more 
important from a public health perspective than improvements by HIV-positive 
women.  
 
Future research directions 
Little is known about women’s decisions related to condom use following HIV 
diagnosis. Such decisions are tied to the type of partner (e.g., husband or boyfriend 
vs. casual partner), his interest in and willingness to use condoms, his serostatus, 
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and the level of communication between partners about these topics. Many studies 
have shown that condom promotion counseling is more successful when both 
members of the partnership receive counseling,
121
 but once again, prospective 
comparisons are lacking.  An analysis of short- and long-term changes in condom 
use behavior within couples, particularly serodiscordant couples, would be 
informative. 
 
A significant limitation of these analyses is reliance on self-reported condom use 
behavior. If biological assays could measure sexual frequency and condom use, 
reliance on self-reported measures would no longer be necessary, and potential 
social desirability and recall biases could be reduced. However, no sufficiently 
sensitive and specific assay exists for such measurements. Current detection 
methods that identify presence of Y chromosome or prostate specific antigen differ 
substantially with self-reported behavior; whether this is due to misreporting or 
mismeasurement of the biological outcome is not known.
213-217
 Future techniques 
will likely also have limitations related to half-life (for example, the decay of their 
ability to detect unprotected sex over time). Repetition of these analyses over 
shorter and longer time periods, and using different outcome classifications (for 
example, use of condoms at the last sex act rather than in a typical month) to 
determine whether findings are similar would be worthwhile to evaluate the 
robustness of our findings. 
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A further research goal is to prospectively explore changes in other risky behaviors 
following HIV diagnosis. We focused only on changes in male condom use in our 
analyses, when in fact women could chose to modify other aspects of their behavior 
in response to HIV diagnosis. In some populations, other types of behavior change 
may be more common and have greater impact in reducing subsequent HIV 
transmission. 
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